Anti-egfr / her3 antibodies and uses thereof

HK40137498APending Publication Date: 2026-09-11BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126873
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-29
Filing Date
2026-07-30
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to anti-EGFR / HER3 antibodies, antibody drug conjugates (ADCs) derived therefrom, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480082746.3 (22) Application Date 2024.12.28 (66) Domestic Priority Data PCT / CN2023 / 143082 2023.12.29 CN (85) PCT International Application Entering National Phase Date 2026.06.26 (86) PCT International Application Application Data PCT / CN2024 / 143476 2024.12.28 (87) PCT International Application Publication Data WO2025 / 140662 EN 2025.07.03 (71) Applicant Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. Address 102600 No. 12, Baoshen South Street, Daxing Biomedical Industry Base, Daxing District, Beijing (72) Inventors: Li Zhuolin, Shang Chengzhang, Yang Yi, Shen Yuelei (74) Patent Agency: China Council for the Promotion of International Trade Patent & Trademark Office Co., Ltd. 11038 Patent Attorney: Cheng Yingying (51) Int.Cl. C07K 16 / 46 (2006.01) C07K 16 / 28 (2006.01) C07K 16 / 32 (2006.01) C12N 15 / 13 (2006.01) A61K 31 / 4745 (2006.01) A61K 47 / 68 (2006.01) A61K 39 / 395 (2006.01) A61P 35 / 00 (2006.01) (54) Title of Invention: Anti-EGFR / HER3 Antibody and Its Use (57) Abstract This disclosure relates to anti-EGFR / HER3 antibodies, antibody-drug conjugates (ADCs) derived therefrom, and their uses. Claims 7 pages Description 54 pages Sequence Listing (Electronic Publication) Drawings 19 pages CN 122459348 A 2026.07.24 CN 1 22 45 93 48 A 1. An anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, comprising: a first antigen-binding domain specifically binding to EGFR and a second antigen-binding domain specifically binding to HER3. 2. The anti-EGFR / HER3 antibody or an antigen-binding fragment thereof according to claim 1, wherein the first antigen-binding domain comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1); and the second antigen-binding domain comprises a second heavy chain variable region (VH2) and a second light chain variable region (VL2). 3. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to claim 2, wherein the first heavy chain variable region (VH1) comprises complementarity-determining regions (CDRs) 1, 2, and 3, wherein the VH1 CDR1 region comprises a region that is compatible with selected VH1 regions.The CDR1 amino acid sequence has at least 80% identity with the selected VH1 CDR2 amino acid sequence, the VH1 CDR2 region contains an amino acid sequence with at least 80% identity with the selected VH1 CDR2 amino acid sequence, and the VH1 CDR3 region contains an amino acid sequence with at least 80% identity with the selected VH1 CDR3 amino acid sequence; and the first light chain variable region (VL1) contains CDR1, 2, and 3, wherein the VL1 CDR1 region contains an amino acid sequence with at least 80% identity with the selected VL1 CDR1 amino acid sequence, the VL1 CDR2 region contains an amino acid sequence with at least 80% identity with the selected VL1 CDR2 amino acid sequence, and the VL1 CDR3 region contains an amino acid sequence with at least 80% identity with the selected VL1 CDR3 amino acid sequence, wherein the selected VH1 CDR1, 2, and 3 amino acid sequences, and the selected VL1 CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: (1) As shown in SEQ ID NO: 4-6, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3 respectively; (2) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9 respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3 respectively; (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12 respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3 respectively; (4) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 22-24 respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3 respectively; (5) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 25-27 respectively, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 25-27 respectively. The amino acid sequences of CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3, respectively; and (6) the amino acid sequences of the selected VH1 CDR1, 2, and 3 are as shown in SEQ ID NO: 28-30, respectively, and the amino acid sequences of the selected VL1 CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3, respectively. 4. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to claim 2 or 3, wherein the second heavy chain variable region (VH2) comprises CDR1, 2, and 3, wherein the VH2 CDR1 region comprises an amino acid sequence having at least 80% identity with the selected VH2 CDR1 amino acid sequence, and the VH2 CDR2 region comprises an amino acid sequence having at least 80% identity with the selected VH2 CDR1 amino acid sequence.The CDR2 amino acid sequence has at least 80% identity with the amino acid sequence, and the VH2 CDR3 region contains an amino acid sequence that has at least 80% identity with the selected VH2 CDR3 amino acid sequence; and the second light chain variable region (VL2) contains CDR1, 2 and 3, wherein the VL2 CDR1 region contains an amino acid sequence that has at least 80% identity with the selected VL2 CDR1 amino acid sequence, the VL2 CDR2 region contains an amino acid sequence that has at least 80% identity with the selected VL2 CDR2 amino acid sequence, and the VL2 CDR3 region contains an amino acid sequence that has at least 80% identity with the selected VL2 CDR3 amino acid sequence, wherein the selected VH2 CDR1, 2 and 3 amino acid sequences and the selected VL2 CDR1, 2 and 3 amino acid sequences are one of the following: (1) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; Claims 1 / 7 page 2 CN 122459348 A (2) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (3) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (4) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 31-33, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (5) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 34-36, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 19-21, respectively; As shown in 1-3; and (6) the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 37-39, and the selected VL2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3. 5. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-4, wherein (1) the selected VH1 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 4-6, the selected VL1 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 37-39, and the selected VL2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VH2 CDR1, 2, 3 amino acid sequences are shown in SEQ ID NO: 1-3, and the selected VL ...The amino acid sequences of CDR1, 2, and 3 are shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (2) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3. (3) The amino acid sequences of CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3; (4) The selected amino acid sequences of VH1 CDR1, 2, and 3 are as shown in SEQ ID NO: 10-12, the selected amino acid sequences of VL1 CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3, the selected amino acid sequences of VH2 CDR1, 2, and 3 are as shown in SEQ ID NO: 16-18, and the selected amino acid sequences of VL2 CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3; or (5) The selected amino acid sequences of VH1 CDR1, 2, and 3 are as shown in SEQ ID NO: 10-12, the selected amino acid sequences of VL1 CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3, the selected amino acid sequences of VH2 CDR1, 2, and 3 are as shown in SEQ ID NO: 19-21, and the selected amino acid sequences of VL2 CDR1, 2, and 3 are as shown in SEQ ID NO: 1-3. 6. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 41, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.40 has a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity. 7. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 42, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40. 8. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40. 9. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40. 10. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45.NO: 43 has a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 46, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40. 11. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-10, wherein the VH1 comprises an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL1 comprises an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 41 and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 42 and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 43 and the selected VL sequence is SEQ ID NO: 40. 12. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-11, wherein the VH1 comprises VH1 CDR1, VH1 CDR2, and VH1 CDR3 identical to VH CDR1, VH CDR2, and VH CDR3 of the selected VH sequence; and the VL1 comprises VL1 CDR1, VL1 CDR2, and VL1 CDR3 identical to VL CDR1, VL CDR2, and VL CDR3 of the selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 41, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 42, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 43, and the selected VL sequence is SEQ ID NO: 40. 13. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-12, wherein the VH2 comprises an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL2 comprises an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1)(1) The selected VH sequence is SEQ ID NO: 44 and the selected VL sequence is SEQ ID NO: 40; (2) The selected VH sequence is SEQ ID NO: 45 and the selected VL sequence is SEQ ID NO: 40; and (3) The selected VH sequence is SEQ ID NO: 46 and the selected VL sequence is SEQ ID NO: 40. 14. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-13, wherein the VH2 comprises VH2 CDR1, VH2 CDR2, and VH2 CDR3 identical to the VH CDR1, VH CDR2, and VH CDR3 of the selected VH sequence; and the VL2 comprises VL2 CDR1, VL2 CDR2, and VL2 CDR3 identical to the VL CDR1, VL CDR2, and VL CDR3 of the selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 44, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 45, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 46, and the selected VL sequence is SEQ ID NO: 40. ID NO: 40. 15. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-14, wherein VH1 comprises the sequence of SEQ ID NO: 41 and VL1 comprises the sequence of SEQ ID NO: 40. 16. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-14, wherein VH1 comprises the sequence of SEQ ID NO: 42 and VL1 comprises the sequence of SEQ ID NO: 40. 17. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-14, wherein VH1 comprises the sequence of SEQ ID NO: 43 and VL1 comprises the sequence of SEQ ID NO: 40. 18. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-17, wherein VH2 comprises the sequence of SEQ ID NO: 44 and VL2 comprises the sequence of SEQ ID NO: 40. 19. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-17, wherein the VH2 comprises the sequence of SEQ ID NO: 45 and the VL2 comprises the sequence of SEQ ID NO: 40.20. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 2-17, wherein the VH2 comprises the sequence of SEQ ID NO: 46 and the VL2 comprises the sequence of SEQ ID NO: 40. 21. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 1-20, wherein the first antigen-binding domain specifically binds to human or monkey EGFR; and / or the second antigen-binding domain specifically binds to human or monkey HER3. 22. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 1-21, wherein the first antigen-binding domain is human or humanized; and / or the second antigen-binding domain is human or humanized. 23. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 1-22, wherein the antibody is a multispecific antibody (e.g., a bispecific antibody). 24. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 1-23, wherein the first antigen-binding domain is a single-chain variable fragment (scFv); and / or the second antigen-binding domain is scFv. 25. An anti-EGFR / HER3 antibody or an antigen-binding fragment thereof according to any one of claims 2-24, wherein the first light chain variable region and the second light chain variable region are identical. 26. An anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof cross-competes with an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof according to any one of claims 1-25. 27. A nucleic acid comprising a polynucleotide encoding an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof according to any one of claims 1-26. 28. A vector comprising the nucleic acid of claim 27. 29. A cell comprising the vector of claim 28. 30. The cell of claim 29, wherein the cell is a CHO cell. 31. A cell comprising the nucleic acid of claim 27. 32. A method for generating an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, the method comprising (a) culturing the cells under conditions sufficient to cause the cells of any one of claims 29-31 to generate the anti-EGFR / HER3 antibody or an antigen-binding fragment thereof; and (b) collecting the anti-EGFR / HER3 antibody or an antigen-binding fragment thereof generated by the cells. Claims 4 / 7 pages 5 CN 122459348 A 33. An anti-EGFR / HER3 antibody-drug conjugate (ADC), the antibody-drug conjugate comprising a covalently bounded therapeutic agent.33. The anti-EGFR / HER3 antibody or antigen-binding fragment thereof as described in any one of claims 1-26. 34. The anti-EGFR / HER3 antibody drug conjugate of claim 33, wherein the therapeutic agent is a cytotoxic agent or a cell growth inhibitor. 35. The anti-EGFR / HER3 antibody drug conjugate of claim 33 or 34, wherein the therapeutic agent is MMAE or MMAF. 36. The antibody drug conjugate of claim 33, wherein the therapeutic agent is selected from (CPT-1), (CPT-2), (CPT-3), or (CPT-4). 37. The antibody drug conjugate of claim 33 or 36, wherein the therapeutic agent is linked to the antibody or antigen-binding fragment thereof via a linker. 38. The antibody drug conjugate of claim 37, wherein the linker has the following structure: [Insert structure here]. 39. The antibody-drug conjugate according to any one of claims 33 and 36-38, wherein the antibody-drug conjugate has the following structure: (Claims 5 / 7, page 6, CN 122459348 A) or, where n = 1-8; wherein “Ab” represents the antibody or its antigen-binding fragment. 40. A method of treating a subject suffering from cancer, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising an anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 1-26, or an anti-EGFR / HER3 antibody-drug conjugate according to any one of claims 33-39. 41. The method of claim 40, wherein the subject suffers from cancer expressing EGFR and / or HER3 (e.g., simultaneously expressing EGFR and HER3). 42. The method of claim 40 or 41, wherein the cancer is esophageal cancer, colorectal cancer, gastric cancer, breast cancer, endometrial cancer, lung cancer, melanoma, ovarian cancer, bladder cancer, non-Hodgkin's lymphoma, head and neck cancer, pancreatic cancer, and cervical cancer. 43. The method of any one of claims 40-42, wherein the subject is a human. 44. The method of any one of claims 40-43, wherein the method further comprises administering an anti-PD1 antibody to the subject. 45. The method of any one of claims 40-44, wherein the method further comprises administering chemotherapy to the subject. 46. A method for reducing tumor growth rate, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as claimed in any one of claims 1-26, or an anti-EGFR / HER3 antibody pharmaceutical conjugate as claimed in any one of claims 33-39. Claims 6 / 7 pages 7 CN 122459348 A47. A method of killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described in any one of claims 1-26, or an anti-EGFR / HER3 antibody drug conjugate as described in any one of claims 33-39. 48. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and (a) an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described in any one of claims 1-26, and / or (b) an anti-EGFR / HER3 antibody drug conjugate as described in any one of claims 33-39. 49. An anti-EGFR / HER3 antibody drug conjugate (ADC) comprising a therapeutic agent covalently bound to a bispecific antibody or an antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment comprising a first antigen-binding domain specifically binding to EGFR and a second antigen-binding domain specifically binding to HER3. Claims 7 / 7 Page 8 CN 122459348 A Anti-EGFR / HER3 Antibody and Its Use

[0001] This application claims the benefit of PCT application No. PCT / CN2023 / 143082, filed on December 29, 2023. The entire contents of which are incorporated herein by reference. Technical Field

[0002] This disclosure relates to multispecific anti-EGFR (epidermal growth factor receptor) / HER3 (human epidermal growth factor receptor 3) antibodies (e.g., bispecific antibodies or antigen-binding fragments thereof), and antibody-drug conjugates derived therefrom. Background Art

[0003] Bispecific antibodies are artificial proteins that can simultaneously bind to two different types of antigens or two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, dual targeting of different disease mediators, and delivery of payloads to target sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and belintomab (anti-CD19 and anti-CD3) has been a significant milestone in the development of bispecific antibodies.

[0004] Bispecific antibodies have a variety of applications; therefore, there is a need to continue developing various therapeutic agents based on bispecific antibodies. Summary of the Invention

[0005] This disclosure relates to anti-EGFR / HER3 antibodies or antigen-binding fragments thereof, wherein the antibody or antigen-binding fragment specifically binds to EGFR and HER3. In some embodiments, the antibody or antigen-binding fragment has the same light chain variable region. In some embodiments, the antibody or antigen-binding fragment has a common light chain. This disclosure also relates to antibody-pharmaceutical conjugates derived from these anti-EGFR / HER3 antibodies.

[0006] In one aspect, this disclosure relates to an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, comprising: a first antigen-binding domain that specifically binds to EGFR; and a second antigen-binding domain that specifically binds to HER3.

[0007] In some embodiments, the first antigen-binding domain includes a first heavy chain variable region (VH1) and a first light chain variable region (VL1); and the second antigen-binding domain includes a second heavy chain variable region (VH2) and a second light chain variable region (VL2).

[0008] In some embodiments, the first heavy chain variable region (VH1) includes complementarity-determining regions (CDRs) 1, 2, and 3, wherein the VH1 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, and the VH1 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence; and

[0009] the first light chain variable region (VL1) includes CDRs 1, 2, and 3, wherein the VL1 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VL1 CDR1 amino acid sequence, the VL1 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VL1 CDR2 amino acid sequence, and the VL1 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VL1 CDR3 amino acid sequence. The selected VH1 CDR1, 2, and 3 amino acid sequences and the selected VL1 CDR1, 2, and 3 amino acid sequences are as follows: (1) The selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 4-6, and the selected VL1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (2) The selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 7-9, and the selected VL1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 10-12, and the selected VL1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively; (4) The selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, respectively. As shown in 22-24, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (5) Selected VH1The amino acid sequences of CDR1, 2, and 3 are shown in SEQ ID NO: 25-27, and the selected amino acid sequences of VL1 CDR1, 2, and 3 are shown in SEQ ID NO: 1-3; and (6) the selected amino acid sequences of VH1 CDR1, 2, and 3 are shown in SEQ ID NO: 28-30, and the selected amino acid sequences of VL1 CDR1, 2, and 3 are shown in SEQ ID NO: 1-3.

[0010] In some embodiments, the second heavy chain variable region (VH2) includes CDR1, 2, and 3, wherein the VH2 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VH2 CDR1 amino acid sequence, the VH2 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VH2 CDR2 amino acid sequence, and the VH2 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VH2 CDR3 amino acid sequence; and

[0011] the second light chain variable region (VL2) includes CDR1, 2, and 3, wherein the VL2 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VL2 CDR1 amino acid sequence, the VL2 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VL2 CDR2 amino acid sequence, and the VL2 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VL2 CDR3 amino acid sequence, wherein the selected VH2 The amino acid sequences of CDR1, 2, and 3 and the selected VL2 CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3; (2) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3; (3) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3; (4) The selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 31-33, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3; ID NO: 1-3; (5) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 34-36, and the selected VL2The amino acid sequences of CDR1, 2, and 3 are shown in SEQ ID NO: 1-3, respectively; and (6) the amino acid sequences of CDR1, 2, and 3 of the selected VH2 are shown in SEQ ID NO: 37-39, respectively, and the amino acid sequences of CDR1, 2, and 3 of the selected VL2 are shown in SEQ ID NO: 1-3, respectively.

[0012] In some embodiments, (1) the selected VH1 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 4-6, the selected VL1 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 1-3; Specification 2 / 54 pages 10 CN 122459348 A (2) the selected VH1 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 4-6, the selected VL1 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, 3 amino acid sequences are as shown in SEQ ID NO: 1-3; (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 4-6, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (4) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (5) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: As shown in 7-9, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3.(6) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (7) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; (8) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: As shown in 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3; or (9) the selected VH1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are as shown in SEQ ID NO: 1-3.

[0013] In some embodiments, the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 41, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0014] In some embodiments, the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 41.The first light chain variable region contains a sequence having at least 80%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0015] In some embodiments, the first heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 41, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 46, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0016] In some embodiments, the first heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 42, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0017] In some embodiments, the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 42, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.40 has a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity.

[0018] In some embodiments, the first heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 42, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 46, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0019] In some embodiments, the first heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0020] In some embodiments, the first heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0021] In some embodiments, the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, and the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 46.The second light chain variable region contains a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40.

[0022] In some embodiments, the VH1 contains an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL1 contains an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 41, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 42, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 43, and the selected VL sequence is SEQ ID NO: 40.

[0023] In some embodiments, the VH1 comprises the same VH1 CDR1, VH1 CDR2, and VH1 CDR3 as the VH CDR1, VH CDR2, and VH CDR3 of the selected VH sequence; and the VL1 comprises the same VL1 CDR1, VL1 CDR2, and VL1 CDR3 as the VL CDR1, VL1 CDR2, and VL1 CDR3 of the selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 41, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 42, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 43, and the selected VL sequence is SEQ ID NO: 40.

[0024] In some embodiments, the VH2 comprises an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL2 comprises an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 44, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 45, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 46, and the selected VL sequence is SEQ ID NO: 40.

[0025] In some embodiments, the VH2 comprises the same VH2 CDR1, VH2 CDR2, and VH2 CDR3 as the VH CDR1, VH CDR2, and VH CDR3 of the selected VH sequence; and the VL2 comprises the same VL2 CDR1, VL2 CDR2, and VL2 CDR3 as the VL CDR1, VL CDR2, and VL CDR3 of the selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) the selected VH sequence is SEQ ID NO: 44, and the selected VL sequence is SEQ ID NO: 40; (2) the selected VH sequence is SEQ ID NO: 45, and the selected VL sequence is SEQ ID NO: 40; and (3) the selected VH sequence is SEQ ID NO: 46, and the selected VL sequence is SEQ ID NO: 40.

[0026] In some embodiments, VH1 comprises the sequence of SEQ ID NO: 41, and VL1 comprises the sequence of SEQ ID NO: 40.

[0027] In some embodiments, VH1 comprises the sequence of SEQ ID NO: 42, and VL1 comprises the sequence of SEQ ID NO: 40.

[0028] In some embodiments, VH1 comprises the sequence of SEQ ID NO: 43, and VL1 comprises the sequence of SEQ ID NO: 40.

[0029] In some embodiments, VH2 comprises the sequence of SEQ ID NO: 44, and VL2 comprises the sequence of SEQ ID NO: 40.

[0030] In some embodiments, VH2 comprises the sequence of SEQ ID NO: 45, and VL2 comprises the sequence of SEQ ID NO: 40.

[0031] In some embodiments, VH2 comprises the sequence of SEQ ID NO: 46, and VL2 comprises the sequence of SEQ ID NO: 40.

[0032] In some embodiments, the first antigen-binding domain specifically binds to human or monkey EGFR; and / or the second antigen-binding domain specifically binds to human or monkey HER3.

[0033] In some embodiments, the first antigen-binding domain is human or humanized; and / or the second antigen-binding domain is human or humanized.

[0034] In some embodiments, the antibody is a multispecific antibody (e.g., a bispecific antibody).

[0035] In some embodiments, the first antigen-binding domain is a single-chain variable fragment (scFv); and / or the second antigen-binding domain is scFv.

[0036] In some embodiments, the first light chain variable region and the second light chain variable region are identical.

[0037] In one aspect, this disclosure relates to an anti-EGFR / HER3 antibody or antigen-binding fragment thereof that competes with the anti-EGFR / HER3 antibody or antigen-binding fragment thereof described herein (page 5 / 54, CN 122459348 A).

[0038] In one aspect, this disclosure relates to a nucleic acid comprising a polynucleotide encoding the anti-EGFR / HER3 antibody or antigen-binding fragment thereof described herein.

[0039] In one aspect, this disclosure relates to a vector comprising the nucleic acid described herein.

[0040] In one aspect, this disclosure relates to a cell comprising the vector described herein.

[0041] In some embodiments, the cell is a CHO cell.

[0042] In one aspect, this disclosure relates to a cell comprising the nucleic acid described herein.

[0043] In one aspect, this disclosure relates to a method for generating an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, the method comprising

[0044] (a) culturing the cells under conditions sufficient to cause the cells described herein to generate the anti-EGFR / HER3 antibody or an antigen-binding fragment thereof; and

[0045] (b) collecting the anti-EGFR / HER3 antibody or an antigen-binding fragment thereof generated by the cells.

[0046] In one aspect, this disclosure relates to an anti-EGFR / HER3 antibody-drug conjugate (ADC) comprising a therapeutic agent covalently bound to the anti-EGFR / HER3 antibody or an antigen-binding fragment thereof described herein.

[0047] In some embodiments, the therapeutic agent is a cytotoxic agent or a cell growth inhibitor.

[0048] In some embodiments, the therapeutic agent is MMAE or MMAF.

[0049] In some embodiments, the therapeutic agent is selected from (CPT-1), (CPT-2), (CPT-3), or (CPT-4).

[0050] In some embodiments, the therapeutic agent is linked to an antibody or its antigen-binding fragment via a linker. In some embodiments, the linker has the following structure: (See specification 6 / 54 page 14 CN 122459348 A).

[0051] In some embodiments, the antibody-drug conjugate has the following structure: Or, in some embodiments, n = 1-8; in some embodiments, “Ab” represents the antibody or its antigen-binding fragment.

[0052] In some embodiments, the drug-antibody ratio (DAR) is approximately 4 or 8.

[0053] In one aspect, this disclosure relates to a method of treating a subject suffering from cancer, the method comprising: applying the drug to the antibody via the specification 7 / 54 page 15 CN 122459348 A.The subject is administered a therapeutically effective amount of the composition, said composition comprising the anti-EGFR / HER3 antibody described herein or an antigen-binding fragment thereof, or the anti-EGFR / HER3 antibody-drug conjugate described herein.

[0054] In some embodiments, the subject has cancer expressing EGFR and / or HER3 (e.g., simultaneously expressing EGFR and HER3).

[0055] In some embodiments, said cancer is esophageal cancer, colorectal cancer, gastric cancer, breast cancer, endometrial cancer, lung cancer, melanoma, ovarian cancer, bladder cancer, non-Hodgkin's lymphoma, head and neck cancer, pancreatic cancer, lung adenocarcinoma, and cervical cancer.

[0056] In some embodiments, the subject is a human.

[0057] In some embodiments, the method further includes administering an anti-PD1 antibody to the subject.

[0058] In some embodiments, the method further includes administering chemotherapy to the subject.

[0059] In one aspect, this disclosure relates to a method for reducing the growth rate of a tumor, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described herein, or an anti-EGFR / HER3 antibody pharmaceutical conjugate as described herein.

[0060] In one aspect, this disclosure relates to a method for killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described herein, or an anti-EGFR / HER3 antibody pharmaceutical conjugate as described herein.

[0061] In one aspect, this disclosure relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and

[0062] (a) an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described herein, and / or

[0063] (b) an anti-EGFR / HER3 antibody pharmaceutical conjugate as described herein.

[0064] In one aspect, this disclosure relates to an anti-EGFR / HER3 antibody-drug conjugate (ADC) comprising a therapeutic agent covalently bound to a bispecific antibody or an antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment comprising: a first antigen-binding domain specifically binding to EGFR; and a second antigen-binding domain specifically binding to HER3.

[0065] As used herein, the term "antigen-binding domain" refers to one or more protein domains (e.g., formed from amino acids from a single polypeptide or from amino acids from two or more polypeptides (e.g., the same or different polypeptides)) capable of specifically binding to one or more different antigens (e.g., effector antigens or control antigens). In some embodiments, the antigen-binding domain may bind to antigens or epitopes with similar specificity and affinity to naturally occurring antibodies.In some embodiments, the antigen-binding domain may be an antibody or a fragment thereof. An example of an antigen-binding domain is an antigen-binding domain formed by a VH-VL dimer. In some embodiments, the antigen-binding domain may include an alternative scaffold. In some embodiments, the antigen-binding domain is VHH. Non-limiting examples of antigen-binding domains are described herein. Other examples of antigen-binding domains are known in the art. In some embodiments, the antigen-binding domain may bind a single antigen (e.g., one of an effector antigen and a control antigen). In other embodiments, the antigen-binding domain may bind two different antigens (e.g., an effector antigen and a control antigen).

[0066] As used herein, the term "antibody" is used in its broadest sense and includes certain types of immunoglobulin molecules that include one or more antigen-binding domains that specifically bind an antigen or epitope. Antibodies specifically include, for example, intact antibodies (e.g., intact immunoglobulins), antibody fragments, bispecific antibodies, and multispecific antibodies. An example of an antibody is a protein complex comprising two heavy chains and two light chains. Other examples of antibodies are described herein.

[0067] As used herein, the term "multispecific antibody" is an antibody that includes two or more different antigen-binding domains that commonly bind to two or more different epitopes. The two or more different epitopes can be epitopes of the same antigen (e.g., a single polypeptide present on the cell surface) or different antigens (e.g., different proteins present on the same cell or different cell surfaces). In some aspects, a multispecific antibody binds two different epitopes (i.e., a "bispecific antibody"). In some aspects, a multispecific antibody binds three different epitopes (i.e., a "trispecific antibody"). In some aspects, a multispecific antibody binds four different epitopes (i.e., a "tetraspecific antibody"). In some aspects, a multispecific antibody binds five different epitopes (i.e., a "pentaspecific antibody"). Each binding specificity can be present in any suitable valence state. Non-limiting examples of multispecific antibodies are described herein.

[0068] As used herein, the term "bispecific antibody" refers to an antibody that binds two different epitopes. Epitopes can be on the same antigen or on different antigens.

[0069] As used herein, the term "common light chain" refers to a light chain that can interact with two or more different heavy chains to form different antigen-binding sites, wherein these different antigen-binding sites can specifically bind different antigens or epitopes. Similarly, the term "common light chain variable region" refers to a light chain variable region that can interact with two or more different heavy chain variable regions to form different antigen-binding sites, wherein these different antigen-binding sites can specifically bind different antigens or epitopes. In some embodiments, the antibody or its antigen-binding fragment may have a common light chain. In some embodimentsIn this context, anti-EGFR / HER3 antibodies or their antigen-binding fragments may have a common light chain variable region.

[0070] As used herein, the term "anti-EGFR / HER3 antibody or its antigen-binding fragment" refers to an antibody or antigen-binding fragment that binds to both EGFR and HER3.

[0071] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Methods and materials used in this invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In case of conflict, this specification (including definitions) shall prevail.

[0072] Other features and advantages of the invention will become apparent from the detailed description and drawings below, as well as from the claims.

[0073] Figure 1 shows the heavy chain variable region and light chain variable region CDR sequences of the anti-EGFR antigen-binding domain (9F3, 9D2, and 9A6) and anti-HER3 antigen-binding domain (1B2, 3E1, and 3G6) in anti-EGFR / HER3 antibodies as defined by Kabat.

[0074] Figure 2 shows the heavy chain variable region and light chain variable region CDR sequences of the anti-EGFR antigen-binding domain (9F3, 9D2, and 9A6) and anti-HER3 antigen-binding domain (1B2, 3E1, and 3G6) in anti-EGFR / HER3 antibodies as defined by Chothia.

[0075] Figure 3 shows the amino acid sequences discussed in this disclosure.

[0076] Figure 4 shows the mean tumor volume of different groups of B-NDG mice injected with NUGC-4 cells and treated with phosphate-buffered saline (PBS) or ADC.

[0077] Figure 5 shows the average tumor volume of different groups of B-NDG mice injected with NCI-H292 cells and treated with PBS or ADC.

[0078] Figure 6 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived gastric tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0079] Figure 7 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived gastric tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0080] Figure 8 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived colorectal tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0081] Figure 9 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived colorectal tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0082] Figure 10 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived colorectal tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0083] Figure 11 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived lung tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0084] Figure 12 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived lung tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0085] Figure 13 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived colorectal tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0086] Figure 14 shows the average tumor volume of different groups of B-NDG mice inoculated with patient-derived colorectal tumor fragments (2 mm × 2 mm × 2 mm) and treated with PBS or ADC.

[0087] Figure 15 illustrates the blocking effect of anti-EGFR / HER3 antibodies and their ADCs on EGF-induced signal transduction.

[0088] Figure 16 illustrates the blocking effect of anti-EGFR / HER3 antibodies and their ADCs on NGR1-induced signal transduction.

[0089] Figure 17 illustrates the blocking effect of anti-EGFR / HER3 antibodies and their ADCs on NGR1-induced signal transduction. Detailed Description

[0090] Bispecific antibodies or antigen-binding fragments thereof are artificial proteins capable of simultaneously binding to two different epitopes (e.g., on two different antigens). In some embodiments, the bispecific antibody or its antigen-binding fragment may have two arms. Each arm has a heavy chain variable region and a light chain variable region, forming an antigen-binding domain (or antigen-binding region). In some embodiments, the bispecific antibody has a common light chain.

[0091] This disclosure relates to anti-EGFR / HER3 antibodies (e.g., bispecific antibodies or their antigen-binding fragments) that specifically bind to EGFR and HER3, and antibody-drug conjugates derived from these anti-EGFR / HER3 antibodies.

[0092] Anti-EGFR / HER3 antibody

[0093] Epidermal growth factor receptor (EGFR, ErbB1, or HER1) is a 170 kDa type 1 transmembrane glycoprotein encoded by the c-erbB1 proto-oncogene. Epidermal growth factor receptor is a member of the ErbB receptor family, which consists of four closely related receptor tyrosine kinases (EGFR (ErbB-1), HER2 / neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4)).Subfamilies. In many cancer types, mutations affecting EGFR expression or activity may lead to cancer. EGFR signaling is initiated by ligand binding, which subsequently induces conformational changes, homodimerization or heterodimerization of the receptor with other ErbB family members, and trans-autophosphorylation of the receptor, thereby initiating a signal transduction cascade that ultimately affects a variety of cellular functions, including cell proliferation and survival. Increased EGFR expression or kinase activity is associated with a range of human cancers, making EGFR an attractive target for therapeutic intervention. In non-small cell lung cancer, increased EGFR gene copy number and protein expression are associated with a good response to the EGFR tyrosine kinase inhibitor IRESSA™ (gefitinib).

[0094] Binding of ligands such as EGF (epidermal growth factor) to EGFR promotes receptor dimerization, autophosphorylation, activation of the receptor's intracellular cytoplasmic tyrosine kinase domain, and initiates a variety of signal transduction and transactivation pathways, participating in the regulation of DNA synthesis (gene activation) and cell cycle progression or division. Inhibition of EGFR signaling may result in inhibition of one or more EGFRs. In some embodiments, EGFR ligands include EGF, TGFα, heparin-binding EGF (HB-EGF), bimodal protein (AR), and epimodal protein (EPI).

[0095] A detailed description of EGFR can be found in Sabbah, Dima A., Rima Hajjo, and Kamal Sweidan. "Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors." Current topics in medicinal chemistry (2020), the full text of which is incorporated herein by reference.

[0096] HER3 is a unique member of the EGFR family. It is not carcinogenic on its own, but it can cooperate with other receptors to induce tumorigenesis, metastatic events, and drug resistance. HER3 is an attractive target for cancer therapy. Unlike EGFR and HER2, which have been widely targeted by tyrosine kinase inhibitors (TKIs), HER3, due to its extremely low kinase activity, is primarily targeted by monoclonal or bispecific antibodies, either by blocking ligand binding or by preventing heterodimerization with other receptors.

[0097] HER3 expression is ubiquitous in various cancers, including breast cancer, ovarian cancer, colon cancer, gastric cancer, and lung cancer.Skin cancer and pancreatic cancer. High HER3 expression is also associated with disease progression and / or poor prognosis in many cancer types. Although HER3 itself does not cause tumorigenesis, the HER2:HER3 heterodimer has the highest transforming capacity among all possible EGFR family dimers. The stronger oncogenic capacity of this dimer pair makes HER3 essential for HER2-mediated tumorigenesis in a variety of tumor types. In breast cancer cell lines, HER3 has been shown to be essential for maintaining cell viability, while EGFR is not required.

[0098] HER3 expression acts as a bypass mechanism for various targeted therapies, and elevated HER3 signaling leads to resistance to multiple therapeutic agents. For example, resistance to EGFR-targeted therapies can arise by dimerizing with other non-EGFR chaperones, as HER3 dimers with receptors other than EGFR (including HER2 and MET receptors). HER3 expression is also associated with resistance to hormone therapy. HER3 plays an important role in the phosphorylation of HER2 in breast cancer cells, and downregulation of HER3 reverses the resistance to the anti-estrogen receptor (ER) tamoxifen in breast cancer cell lines.

[0099] For a detailed review of HER3 and its functions, see Haikala, Heidi M. and Pasi A. Jänne. "Thirty Years of HER3: From Basic Biology to Therapeutic Interventions 30 Years of HER3." Clinical Cancer Research 27.13 (2021): 3528-3539; and Mishra, Rosalin et al., "HER3 signaling and targeted therapy in cancer." Oncology reviews 12.1 (2018); Liu, Xiaolong et al., "Development of effective therapeutics targeting HER3 for cancer treatment." Biological procedures online 21.1 (2019): 1-10; the full text of which is incorporated herein by reference.

[0100] In some embodiments, the bispecific anti-EGFR / HER3 antibody described herein may be designed as an IgG1 subtype structure with a club-and-mortar (KIH) mutation, which promotes heterodimerization and avoids mismatch between the two heavy chains. In some embodiments, the bispecific anti-EGFR / HER3 antibody has a higher endocytosis rate than the corresponding monoclonal antibody or control bispecific antibody.

[0101] In some embodiments, the bispecific anti-EGFR / HER3 antibody described herein may be conjugated with a therapeutic agent to form an antibody-drug conjugate (ADC). In some embodiments, the drug-to-antibody ratio (DAR) of the ADC described herein is about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, or about 4.7. In some implementations, the DAR of the ADC described herein is approximately 3.5 to 4.5, approximately 3.6 to 4.5, approximately 3.7 to 4.5, approximately 3.8 to 4.5, approximately 3.9 to 4.5, approximately 4.0 to 4.5, approximately 4.1 to 4.5, approximately 4.2 to 4.5, approximately 4.3 to 4.5, approximately 4.4 to 4.5, approximately 3.5 to 4.4, approximately 3.6 to 4.4, approximately 3.7 to 4.4, approximately 3.8 to 4.4, approximately 3.9 to 4.4, approximately 4.0 to 4.4, approximately 4.1 to page 11 / 54 of the specification. (CN 122459348 A) About 4.4, about 4.2 to about 4.4, about 4.3 to about 4.4, about 3.5 to about 4.3, about 3.6 to about 4.3, about 3.7 to about 4.3, about 3.8 to about 4.3, about 3.9 to about 4.3, about 4.0 to about 4.3, about 4.1 to about 4.3, about 4.2 to about 4.3, about 3.5 to about 4.2, about 3.6 to about 4.2, about 3.7 to about 4.2, about 3.8 to about 4.2, about 3.9 to about 4.2, about 4.0 to about 4.2, about 4.1 to about 4.2, about 3.5 to about 4.1, about 3.6 to about 4.1, about 3.7 to about 4.1, about 3.8 to about 4.1, about 3.9 to about 4.1, about 4 0 to about 4.1, about 3.5 to about 4.0, about 3.6 to about 4.0, about 3.7 to about 4.0, about 3.8 to about 4.0, about 3.9 to about 4.0, about 3.5 to about 3.9, about 3.6 to about 3.9, about 3.7 to about 3.9, about 3.8 to about 3.9, about 3.5 to about 3.8, about 3.6 to about 3.8, about 3.7 to about 3.8, about 3.5 to about 3.7, about 3.6 to about 3.7, or about 3.5 to about 3.6. In some implementations, the DAR of the ADC described herein is approximately 7.5 to 8.5, approximately 7.6 to 8.5, approximately 7.7 to 8.5, approximately 7.8 to 8.5, approximately 7.9 to 8.5, approximately 8.0 to 8.5, approximately 8.1 to 8.5, approximately 8.2 to 8.5, approximately 8.3 to 8.5, approximately 8.4 to 8.5, approximately 7.5 to 8.4, approximately 7.6 to 8.4, approximately 7.7 to 8.4, approximately 7.8 to 8.4, approximately 7.9 to 8.4, approximately 8.0 to 8.4, approximately 8.1 to 8.4, approximately 8.2 to 8.4, approximately 8.3 to 8.4, approximately 7....5 to about 8.3, about 7.6 to about 8.3, about 7.7 to about 8.3, about 7.8 to about 8.3, about 7.9 to about 8.3, about 8.0 to about 8.3, about 8.1 to about 8.3, about 8.2 to about 8.3, about 7.5 to about 8.2, about 7.6 to about 8.2, about 7.7 to about 8.2, about 7.8 to about 8.2, about 7.9 to about 8.2, about 8.0 to about 8.2, about 8.1 to about 8.2, about 7.5 to about 8.1, about 7.6 to about 8.1, about 7.7 to about 8.1, about 7.8 to about 8.1, about 7.9 to about 8.1, about 8.0 to about 8.1, about 7.5 to about 8.0, about 7.6 to about 8.0, about 7.7 to about 8.0, about 7.8 to about 8.0, about 7.9 to about 8.0, about 7.5 to about 7.9, About 7.6 to about 7.9, about 7.7 to about 7.9, about 7.8 to about 7.9, about 7.5 to about 7.8, about 7.6 to about 7.8, about 7.7 to about 7.8, about 7.5 to about 7.7, about 7.6 to about 7.7, or about 7.5 to about 7.6.

[0102] In some embodiments, the anti-EGFR / HER3 ADC described herein can effectively inhibit the growth of cancer cells in vitro at concentrations of less than 10 μg / ml, less than 3.33 μg / ml, less than 1.11 μg / ml, less than 0.37 μg / ml, less than 0.12 μg / ml, less than 0.04 μg / ml, or less than 0.01 μg / ml. In some embodiments, the anti-EGFR / HER3 ADC described herein can inhibit the growth of cancer cells (e.g., lung cancer, gastric cancer, or skin cancer) in xenograft mouse models at dose levels less than 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, or 1 mg / kg.

[0103] In some embodiments, the anti-EGFR / HER3 antibody described herein has a common light chain. In some embodiments, the anti-EGFR / HER3 antibody includes an anti-EGFR antigen-binding domain (e.g., 9F3, 9D2, 9A6) or an anti-HER3 antigen-binding domain (e.g., 1B2, 3E1, 3G6). In some embodiments, the anti-EGFR / HER3 antibody has a heavy chain variable region targeting EGFR (e.g., any of the EGFR-targeting VH described herein), a heavy chain variable region targeting HER3 (e.g., any of the HER3-targeting VH described herein), and two identical common light chain variable regions.

[0104] The CDR sequence of the 9F3 antigen-binding domain includes the CDR of the heavy chain variable domain as defined by Kabat (SEQ ID NO: 4-6) and the CDR of the light chain variable domain (SEQ ID NO: 4-6).1-3). CDRs can also be determined by Chothia. Under the definition of Chothia, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NO: 22-24, and the CDR sequences of the light chain variable domain are shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 9F3 are shown in SEQ ID NO: 40 and SEQ ID NO: 41, respectively.

[0105] The CDR sequence of the 9D2 antigen-binding domain includes the CDRs of the heavy chain variable domain (SEQ ID NO: 7-9) and the light chain variable domain (SEQ ID NO: 1-3) as defined by Kabat. CDRs can also be determined by Chothia. Under the definition of Chothia, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NO: 25-27, and the CDR sequences of the light chain variable domain are shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 9D2 are shown in SEQ ID NO: 40 and SEQ ID NO: 42, respectively.

[0106] The CDR sequence of the antigen-binding domain of 9A6 includes the CDR of the heavy chain variable domain as defined by Kabat (SEQ ID NO: 10-12, page 12 / 54 of the specification, 20 CN 122459348 A NO: 10-12) and the CDR of the light chain variable domain (SEQ ID NO: 1-3). The CDR can also be determined by Chothia. Under the definition of Chothia, the CDR sequence of the heavy chain variable domain is shown in SEQ ID NO: 28-30, and the CDR sequence of the light chain variable domain is shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 9A6 are shown in SEQ ID NO: 40 and SEQ ID NO: 43, respectively.

[0107] The CDR sequence of the 1B2 antigen-binding domain includes the CDR of the heavy chain variable domain (SEQ ID NO: 13-15) and the CDR of the light chain variable domain (SEQ ID NO: 1-3) as defined by Kabat. The CDR can also be determined by Chothia. Under Chothia's definition, the CDR sequence of the heavy chain variable domain is shown in SEQ ID NO: 31-33, and the CDR sequence of the light chain variable domain is shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 1B2 are shown in SEQ ID NO: 40 and SEQ ID NO: 44, respectively.

[0108] The CDR sequence of the 3E1 antigen-binding domain includes the CDR of the heavy chain variable domain (SEQ ID NO: 16-18) and the CDR of the light chain variable domain (SEQ ID NO: 1-3) as defined by Kabat.1-3). CDRs can also be determined by Chothia. Under the definition of Chothia, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NO: 34-36, and the CDR sequences of the light chain variable domain are shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 3E1 are shown in SEQ ID NO: 40 and SEQ ID NO: 45, respectively.

[0109] The CDR sequence of the 3G6 antigen-binding domain includes the CDRs of the heavy chain variable domain (SEQ ID NO: 19-21) and the light chain variable domain (SEQ ID NO: 1-3) as defined by Kabat. CDRs can also be determined by Chothia. Under the definition of Chothia, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NO: 37-39, and the CDR sequences of the light chain variable domain are shown in SEQ ID NO: 1-3. The fully human light chain variable region and the fully human heavy chain variable region of 3G6 are shown in SEQ ID NO: 40 and SEQ ID NO: 46, respectively.

[0110] In some embodiments, the anti-EGFR / HER3 antibody described herein may contain one, two or three heavy chain variable regions (CDRs) selected from SEQ ID NO: 4-6, SEQ ID NO: 7-9, SEQ ID NO: 10-12, SEQ ID NO: 13-15, SEQ ID NO: 16-18, SEQ ID NO: 19-21, SEQ ID NO: 22-24, SEQ ID NO: 25-27, SEQ ID NO: 28-30, SEQ ID NO: 31-33, SEQ ID NO: 34-36 and SEQ ID NO: 37-39; and / or one, two or three light chain variable regions (CDRs) selected from SEQ ID NO: 1-3.

[0111] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment may have heavy chain variable regions (VH) including complementarity-determining regions (CDRs) 1, 2, and 3, wherein CDR1 contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR1 amino acid sequence, CDR2 contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR2 amino acid sequence, and CDR3 contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VH CDR3 amino acid sequence; and light chain variable regions (VL) including CDRs 1, 2, and 3, wherein CDR1 contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VL CDR1 amino acid sequence;The CDR2 region contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR2 amino acid sequence, and the CDR3 region contains or is composed of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with the selected VL CDR3 amino acid sequence. The selected VH CDR1, 2, 3 amino acid sequences and the selected VL CDR1, 2, 3 amino acid sequences are shown in Figures 1 and 2.

[0112] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may contain a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 4 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 5 having zero, one, or two amino acid insertions, deletions, or substitutions; and SEQ ID NO: 6 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0113] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three CDRs of the following CDRs: SEQ ID NO: 7 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 8 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 9 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0114] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three CDRs: SEQ ID NO: 10 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 11 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 12 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0115] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 13 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 14 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 15 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0116] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 13 having zero, one, or two amino acid insertions, deletions, or substitutions.The heavy chain variable domain of one, two, or three of the following CDRs: SEQ ID NO: 16 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 17 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 18 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0117] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 19 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 20 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 21 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0118] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 22 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 23 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 24 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0119] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 25 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 26 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 27 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0120] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 28 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 29 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 30 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0121] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 29 having zero, one, or two amino acid insertions, deletions, or substitutions; ...31; SEQ ID NO: 32 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 33 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0122] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 34 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 35 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 36 having zero, one, or two amino acid insertions, deletions, or substitutions. Specification 14 / 54 pages 22 CN 122459348 A

[0123] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a heavy chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 37 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 38 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 39 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0124] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment described herein may comprise a light chain variable domain containing one, two, or three of the following CDRs: SEQ ID NO: 1 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 2 having zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 3 having zero, one, or two amino acid insertions, deletions, or substitutions.

[0125] Insertions, deletions, and substitutions may be within the CDR sequence or at one or both ends of the CDR sequence.

[0126] In some embodiments, the anti-EGFR / HER3 antibody comprises: a heavy chain variable region (VH) comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VH sequence; and a light chain variable region (VL) comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, or 95% identity with a selected VL sequence. In some embodiments, the selected VH sequence is SEQ ID NO: 41, 42, 43, 44, 45, or 46, and the selected VL sequence is SEQ ID NO: 40.

[0127] In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment may have three VHs identical to the CDR of any VH sequence described herein.CDR. In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment may have the same three VL CDRs as any VL sequence described herein.

[0128] This disclosure also provides nucleic acids comprising polynucleotides encoding anti-EGFR / HER3 antibodies. The anti-EGFR / HER3 antibody immunoglobulin heavy chain or immunoglobulin light chain comprises the CDRs shown in Figure 1, Figure 2, or Figure 3. When the polypeptide is paired with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptide binds to EGFR and / or HER3.

[0129] The anti-EGFR / HER3 antibody may also be an anti-EGFR / HER3 antibody variant (including derivatives and conjugates) of the anti-EGFR / HER3 antibody or antibody fragment. Other anti-EGFR / HER3 antibodies provided herein are polyclonal antibodies, monoclonal antibodies, multispecific antibodies (multimeric antibodies, such as bispecific antibodies), fully human antibodies, chimeric antibodies (e.g., human-mouse chimeras), single-chain antibodies, intracellularly generated antibodies (i.e., intrabody antibodies), and their antigen-binding fragments. Anti-EGFR / HER3 antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In some embodiments, the anti-EGFR / HER3 antibody or antigen-binding fragment is an IgG (e.g., IgG1) antibody or its antigen-binding fragment.

[0130] Anti-EGFR / HER3 antibody fragments are suitable for use in the methods provided herein, provided they retain the desired affinity and specificity for EGFR and HER3. Therefore, fragments of anti-EGFR / HER3 antibodies will retain the ability to bind to EGFR and HER3.

[0131] Antibodies and their antigen-binding fragments

[0132] In some embodiments, the multispecific anti-EGFR / HER3 antibody (e.g., a bispecific antibody) comprises an antigen-binding domain derived from an anti-EGFR antibody and an antigen-binding domain derived from an anti-HER3 antibody. These anti-EGFR / HER3 antibodies and their antigen-binding fragments may have various forms.

[0133] Typically, antibodies (also called immunoglobulins) can be composed of two types of polypeptide chains: light chains and heavy chains. The non-limiting anti-EGFR / HER3 antibody of this disclosure can be a complete tetraimmunoglobulin chain antibody comprising two heavy chains and two light chains. The heavy chain of the anti-EGFR / HER3 antibody can be any isotype, including IgM, IgG, IgE, IgA, or IgD; or a subisotype, including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc. The light chain can be a κ light chain or a λ light chain. (Specification 15 / 54 pages 23)CN 122459348 A

[0134] The hypervariable region, called the complementarity-determining region (CDR), forms a loop containing the main antigen-binding surface of the antibody. The four framework regions primarily adopt a β-sheet conformation, and the CDRs form a loop structure connected together and, in some cases, form part of a β-sheet structure. The CDRs in each chain are kept close together by the framework regions and, together with the CDRs from the other chain, contribute to the formation of the antigen-binding domain.

[0135] The method of identifying the CDR region of an antibody by analyzing the amino acid sequence of the antibody is well known, and many definitions of CDRs are commonly used. The Kabat definition is based on sequence variability, and the Chothia definition is based on the location of the structural loop region. These methods and definitions are described in the following: for example, Martin, "Protein sequence and structure analysis of antibody variable domains," Antibody engineering, Springer Berlin Heidelberg, 2001. 422-439; Abhinandan et al., "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains," Molecular immunology 45.14 (2008): 3832-3839; Wu, TT and Kabat, EA (1970) J . Exp. Med. 132: 211-250; Martin et al., Methods Enzymol. 203:121-53 (1991); Morea et al., Biophys Chem. 68(1-3):9-16 (Oct. 1997); Morea et al., J Mol Biol. 275(2):269-94 (Jan .1998); Chothia et al., Nature 342(6252):877-83 (Dec . 1989); Ponomarenko and Bourne, BMC Structural Biology 7:64 (2007); each is incorporated herein by reference in its entirety.

[0136] CDR is important for recognizing antigenic epitopes. As used herein, an "epitaph" is the smallest part of a target molecule that can be specifically bound by the antigen-binding domain of an antibody. The minimum size of an epitope can be about 3, 4, 5, 6 or 7 amino acids, butThese amino acids need not be located in a continuous linear sequence of the primary structure of the antigen, as epitopes can depend on the three-dimensional conformation of the antigen based on its secondary and tertiary structures.

[0137] In some embodiments, the anti-EGFR / HER3 antibody is a complete immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG3, IgM, IgD, IgE, IgA). IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, differing only in their constant regions, particularly their hinges and upper CH2 domains. The sequences and differences of IgG subclasses are known in the art and are described, for example, in the following: Vidarsson et al., "IgG subclasses and allotypes: from structure to effector functions." Frontiers in immunology 5 (2014); Irani et al., "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases." Molecular immunology 67.2 (2015): 171-182; Shakib, Farouk, ed. The human IgG subclasses: molecular analysis of structure, function and regulation. Elsevier, 2016; each of which is incorporated herein by reference in its entirety.

[0138] Anti-EGFR / HER3 antibodies may also be immunoglobulin molecules derived from any species (e.g., human, rodent, mouse, rat, camelid). An antigen-binding domain or antigen-binding fragment is an antibody portion that retains the specific binding activity of the intact antibody; that is, any portion of the antibody capable of specifically binding to an epitope on the target molecule of the intact antibody. These include, for example, Fab, Fab', F(ab')2, and variants of these fragments. Therefore, in some embodiments, an anti-EGFR / HER3 antibody or its antigen-binding fragment may comprise, for example, scFv, Fv, Fd, dAb, bispecific antibodies, bispecific scFv, biantibodies, linear antibodies, single-chain antibody molecules, multispecific antibodies, and any polypeptide containing an antibody-binding domain or a binding domain homologous to an antibody-binding domain. Non-limiting examples of antigen-binding domains include,For example, the heavy chain and / or light chain CDR of an intact antibody, the heavy chain and / or light chain variable region of an intact antibody, the full-length heavy chain or light chain of an intact antibody, or a single CDR derived from the heavy chain or light chain of an intact antibody.

[0139] In some embodiments, the scFv in the anti-EGFR / HER3 antibody has two heavy chain variable domains and two light chain variable domains. In some embodiments, the anti-EGFR / HER3 scFv has two antigen-binding regions, and these two antigen-binding regions may bind to their respective target antigens with different affinities.

[0140] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment may contain one, two, or three heavy chain variable region CDRs selected from Figures 1 and 2.

[0141] In some embodiments, the anti-EGFR / HER3 antibody described herein may be conjugated to a therapeutic agent. Anti-EGFR / HER3 antibody-pharmaceutical conjugates containing the antibody or its antigen-binding fragment may covalently or non-covalently bind to a therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic agent or a cell growth inhibitor (e.g., monomethylaurestatin E, monomethylaurestatin F, cytochalasin B, bacitracin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthraxine, maytansine alkaloids (such as DM-1 and DM-4), diketones, mitoxantrone, photomycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and analogues). In some embodiments, the therapeutic agent is MMAE or MMAF. In some embodiments, the therapeutic agent is coupled via a linker (e.g., a VC linker). For details on the linkers used in the ADC, see Su, Z et al., "Antibody–drug conjugates: Recent advances in linker chemistry." Acta Pharmaceutica Sinica B (2021), the full text of which is incorporated herein by reference.

[0142] In some embodiments, the anti-EGFR / HER3 antibody is a bispecific antibody. Bispecific antibodies can be prepared by modifying the interface between a pair of antibody molecules to maximize the percentage of heterodimers recovered from recombinant cell cultures. For example, the interface may contain at least a portion of the CH3 domain of the antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). A compensatory “cavity” of the same or similar size for the large side chain is created at the interface of the second antibody molecule by the larger amino group.The acidic side chain is replaced with a smaller side chain (e.g., alanine or threonine). This provides a mechanism to increase the yield of the heterodimer relative to other unwanted end products (e.g., homodimer). The method is described, for example, in WO 96 / 27011, which is incorporated herein by reference in its entirety.

[0143] Any anti-EGFR / HER3 antibody or antigen-binding fragment thereof described herein may be conjugated with a stabilizing molecule (e.g., a molecule that increases the half-life of the antibody or antigen-binding fragment thereof in vivo or in solution in a subject). Non-limiting examples of stabilizing molecules include polymers (e.g., polyethylene glycol) or proteins (e.g., serum albumin, such as human serum albumin). Conjugation with a stabilizing molecule may prolong the half-life of the anti-EGFR / HER3 antibody or antigen-binding fragment in vitro (e.g., in tissue cultures or when stored as a pharmaceutical composition) or in vivo (e.g., in humans) or enhance its biological activity.

[0144] Anti-EGFR / HER3 antibodies or antigen-binding fragments thereof may also be in various forms. Many different formats of bispecific antibodies or their antigen-binding fragments are known in the art and described, for example, in Suurs et al., "A review of bispecific antibodies and antibody constructs in oncology and clinical challenges," Pharmacology & therapeutics (2019), which is incorporated herein by reference in its entirety.

[0145] In some embodiments, the anti-EGFR / HER3 antibody is BiTe, (scFv)2, nanobody, nanobody-HSA, DART, TandAb, scDiabody, scDiabody-CH3, scFv-CH-CL-scFv, HSAbody, scDiabody-HAS, or tandem scFv. In some embodiments, the anti-EGFR / HER3 antibody is VHH-scAb, VHH-Fab, dual scFab, F(ab')2, biantibody, crossMab, DAF (dual-component), DAF (quadrivalent-component), DutaMab, DT-IgG, knobs-in-holes co-light chain, knobs-in-holes assembly, charge pair, Fab arm exchange, SEEDbody, LUZ-Y, Fcab, κλ-body, orthogonal Fab, DVD-IgG, IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, scFv-(L)IgG, IgG(L, H)-Fv, IgG(H)-V, V(H)-IgG, IgG(L)-V, V(L)-IgG, KIHIgG-scFab, 2scFv-IgG, IgG-2scFv, scFv4-Ig, Zybody, DVI-IgG, Diabody-CH3, Triple antibody, Micro antibody, Micro antibody, TriBi micro antibody, scFv-CH3 KIH, Fab-scFv, F(ab')2-scFv2, scFv-KIH, Fab-scFv-Fc, Quadrivalent HCAb, scDiabody-Fc, Diabody-Fc, Tandem scFv-Fc, Intracellular antibody, Dock and lock antibody, lmm TAC, IgG-IgG conjugate, Cov-X-Body or scFv1-PEG-scFv2.

[0146] In some embodiments, the anti-EGFR / HER3 antibody may be TrioMab. In TrioMab, the two heavy chains are from different species, with different sequences restricting heavy-light chain pairing.

[0147] In some embodiments, the anti-EGFR / HER3 antibody has two different heavy chains and a common light chain. Heterodimerization of the heavy chains can be performed according to mortis or some other heavy chain pairing techniques.

[0148] In some embodiments, the CrossMAb technology can be used to generate bispecific anti-EGFR / HER3 antibodies. The CrossMAb technology can be used to enforce correct light chain association in bispecific heterodimeric IgG antibodies, allowing the generation of various bispecific antibody formats, including bivalent (1+1), trivalent (2+1), and tetravalent (2+2) bispecific antibodies, as well as antibodies based on non-Fc tandem antigen-binding fragments (Fab). These formats can be derived from any existing antibody pair using domain cross-derivatives without identifying the common light chain, post-translational processing / in vitro chemical combinations, or introducing a set of mutations to enforce correct light chain association. This method is described in Klein et al., "The use of CrossMAb technology for the generation of bi- and multispecific antibodies." MAbs. Vol. 8. No. 6. Taylor & Francis, 2016, which is incorporated herein by reference in its entirety. In some embodiments, the CH1 domain in the heavy chain and the CL domain in the light chain are exchanged.

[0149] The anti-EGFR / HER3 antibody may be a Duobody. The Fab exchange mechanism naturally present in IgG4 antibodies is mimicked in a controlled manner in IgG1 antibodies; this mechanism is called controlled Fab exchange. This format ensures a specific pairing between the heavy and light chains.

[0150] In dual variable domain antibodies (DVD-Ig), an additional VH and variable light chain (VL) domain are added to each N-terminus to achieve bispecific targeting. This format is similar to IgG-scFv, but the added binding domains bind individually to their respective N-termini, rather than the scFv binding to the N-terminus of each heavy chain.

[0151] In scFv-IgG, two scFvs are linked to the C-terminus of the heavy chain (CH3). The scFv-IgG format has two distinct bivalent binding sites and is therefore also referred to as tetravalent. There is no heavy chain and light chain pairing issue in scFv-IgG.

[0152] In some embodiments, anti-EGFR / HER3 antibodies may have an IgG-IgG format. Two complete IgG antibodies are conjugated by chemically linking the C-terminus of the heavy chain.

[0153] Anti-EGFR / HER3 antibodies may also have a Fab-scFv-Fc format. In the Fab-scFv-Fc format, the light chain, heavy chain, and a third chain containing the Fc region and scFv are assembled together. This ensures efficient manufacturing and purification.

[0154] In some embodiments, the anti-EGFR / HER3 antibody may be TF. Three Fab fragments are linked by disulfide bonds. Two fragments target tumor-associated antigens (TAAs), and one fragment targets a hapten. The TF format does not have an Fc region.

[0155] ADAPTIR has two scFvs and binds to each side of the Fc region. It abandons the complete IgG as the basis of its construct but retains the Fc region to prolong the half-life and facilitate purification.

[0156] Dual-Affinity Retargeting (DART) has two peptide chains linked with opposite fragments, so VLA is linked to VHB and VLB is linked to VHA, and their C-termini are fused together by a disulfide bond. In DART, the disulfide bond improves stability compared to BiTE.

[0157] In DART-Fc, the Fc region is attached to the DART structure. It can be generated by combining three chains, two of which are linked by disulfide bonds, as in DART. One chain contains half of the Fc region, which will dimerize with a third chain that expresses only the Fc region. The addition of the Fc region increases the half-life, allowing the effective concentration to be maintained for a longer period of time, avoiding continuous intravenous (IV) administration.

[0158] In tetravalent DART, four peptide chains are combined. Basically, two DART molecules are produced, each having half of the Fc region and dimerizing. This format has the ability to bind to two targets bivalently, and therefore it is a tetravalent molecule.

[0159] Tandem biantibodies (TandAb) contain two biantibodies. Each biantibody consists of one VHA and VLB fragment and one VHA and VLB fragment, which are covalently associated. The two biantibodies are linked by peptide chains. This is in contrast to two scFvThe resulting bispecific antibody exhibits improved stability. It has two bivalent binding sites.

[0160] The ScFv-scFv-toxin comprises a toxin and two scFvs with a stable linker. It can be used for specific delivery of the payload.

[0161] In some embodiments, the anti-EGFR / HER3 antibody is a bispecific antibody. In some embodiments, the bispecific antibody of this disclosure is designed as 1+1 (each target is monovalent) and has an IgG1 subtype structure. This can reduce affinity for cells that express low levels of EGFR and HER3 and increase affinity for cells that co-express EGFR and HER3 to achieve enhanced targeting function.

[0162] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment has a light chain constant region having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 47 and a heavy chain constant region having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with any one of SEQ ID NO: 48 and 49.

[0163] In some embodiments, the anti-EGFR / HER3 antibody includes a KIH mutation. In some embodiments, the anti-EGFR / HER3 includes a first antigen-binding domain that specifically binds to EGFR and a second antigen-binding domain that specifically binds to HER3. In some embodiments, the first antigen-binding domain includes a heavy chain containing one or more club-shaped mutations (club-shaped heavy chain), and the second antigen-binding domain includes a heavy chain containing one or more club-shaped mutations (club-shaped heavy chain). In some embodiments, the first antigen-binding domain includes a heavy chain containing one or more club-shaped mutations (club-shaped heavy chain), and the second antigen-binding domain includes a heavy chain containing one or more club-shaped mutations (club-shaped heavy chain). In some embodiments, the anti-EGFR / HER3 antibody includes a club-shaped heavy chain containing a constant region having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 48. In some embodiments, the anti-EGFR / HER3 antibody comprises a mortise heavy chain, said mortise heavy chain containing a constant region having at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with SEQ ID NO: 49.

[0164] Antibody Characteristics

[0165] Anti-EGFR / HER3 antibodies may include an anti-EGFR antigen-binding domain and any of the anti-HER3 antigen-binding domains described herein.

[0166] This disclosure provides anti-EGFR / HER3 antibodies and antigen-binding fragments thereof that specifically bind to EGFR. These anti-EGFR / HER3 antibodies may be agonists or antagonists. The anti-EGFR / HER3 antibodies or antigen-binding fragments thereof described herein may bind to EGFR and block the binding between EGFR and its ligand. By blocking the binding between EGFR and its ligand, anti-EGFR / HER3 antibodies may inhibit EGFR-related signaling pathways and thus treat cancer. In some embodiments, anti-EGFR / HER3 antibodies or antigen-binding fragments thereof may induce CDC or ADCC.

[0167] The affinity of an antibody for an antigen can be measured using common techniques, including, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and surface plasmon resonance (SPR). Affinity can be derived from the quotient of the self-kinetic rate constant (KD = koff / kon). In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment can bind to EGFR (e.g., human EGFR, monkey EGFR, mouse EGFR, and / or chimeric EGFR) at the following dissociation rates (koff): less than 0.1 s⁻¹, less than 0.01 s⁻¹, less than 0.001 s⁻¹, less than 0.0001 s⁻¹, or less than 0.00001 s⁻¹. In some embodiments, the dissociation rate (koff) is greater than 0.01 s⁻¹, greater than 0.001 s⁻¹, greater than 0.00001 s⁻¹, greater than 0.000001 s⁻¹, or greater than 0.000001 s⁻¹. (Specification 19 / 54 pages, 27 CN 122459348 A-1)

[0168] In some embodiments, the kinetic association rate (kon) is greater than 1 x 10² / Ms, greater than 1 x 10³ / Ms, greater than 1 x 10⁴ / Ms, greater than 1 x 10⁵ / Ms, or greater than 1 x 10⁶ / Ms. In some embodiments, the kinetic association rate (kon) is less than 1 x 10⁵ / Ms, less than 1 x 10⁶ / Ms, or less than 1 x 10⁷ / Ms.

[0169] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment can bind EGFR (e.g., human EGFR, monkey EGFR, mouse EGFR, and / or chimeric EGFR) at the following KD values: less than 1 x 10⁻⁶ M, less than 1 x 10⁻⁷ M, less than 1 x 10⁻⁸ M, less than 1 x 10⁻⁹ M, or less than 1 x 10⁻¹⁰ M. In some implementations, KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. In some embodiments, KD is greater than 1 x 10⁻⁷ M, greater than 1 x 10⁻⁸ M, greater than 1 x 10⁻⁹ M, or greater than 1 x 10⁻¹⁰ M.

[0170] Anti-EGFR / HER3 antibodies or antigen-binding fragments thereof may also include an antigen-binding domain that specifically binds to HER3. The anti-EGFR / HER3 antibodies or antigen-binding fragments thereof described herein can block the binding between HER3 and its ligand. In some embodiments, by binding to HER3, anti-EGFR / HER3 antibodies can also inhibit HER3-related signaling pathways and inhibit cell proliferation, differentiation, and / or metastasis. Therefore, in some embodiments, the anti-EGFR / HER3 antibodies described herein are HER3 agonists. In some embodiments, anti-EGFR / HER3 antibodies are HER3 antagonists.

[0171] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment may bind to HER3 (e.g., human HER3, monkey HER3, mouse HER3, and / or chimeric HER3) at the following dissociation rates (koff): less than 0.1 s⁻¹, less than 0.01 s⁻¹, less than 0.001 s⁻¹, less than 0.0001 s⁻¹, or less than 0.00001 s⁻¹. In some embodiments, the dissociation rate (koff) is greater than 0.01 s⁻¹, greater than 0.001 s⁻¹, greater than 0.0001 s⁻¹, greater than 0.00001 s⁻¹, or greater than 0.000001 s⁻¹.

[0172] In some embodiments, the kinetic association rate (kon) is greater than 1 x 10² / Ms, greater than 1 x 10³ / Ms, greater than 1 x 10⁴ / Ms, greater than 1 x 10⁵ / Ms, or greater than 1 x 10⁶ / Ms. In some embodiments, the kinetic association rate (kon) is less than 1 x 10⁵ / Ms, less than 1 x 10⁶ / Ms, or less than 1 x 10⁷ / Ms.

[0173] Affinity can be derived from the quotient of the kinetic rate constant (KD = koff / kon). In some embodiments, KD is less than 1 x 10⁻⁶ M, less than 1 x 10⁻⁷ M, less than 1 x 10⁻⁸ M, less than 1 x 10⁻⁹ M, or less than 1 x 10⁻¹⁰ M. In some embodiments, KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. In some embodiments, KD is greater than 1 x 10⁻⁷ M, greater than 1 x 10⁻⁸ M, greater than 1 x 10⁻⁹ M, or greater than 1 x 10⁻¹⁰ M.

[0174] Because anti-EGFR / HER3 antibodies (e.g., bispecific antibodies) can bind to both EGFR and HER3 simultaneously, they have a higher binding affinity for cells that simultaneously express EGFR and HER3. Affinity can be used to measure the binding affinity of an antibody to these cells. Affinity refers to the cumulative binding strength of multiple independent non-covalent binding interactions.

[0175] In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment is capable of binding to human HER3 or monkey HER3. In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment is not capable of binding to human HER3 or monkey HER3. In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment is capable of binding to human EGFR or monkey EGFR. In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment is not capable of binding to human EGFR or monkey EGFR.

[0176] In some embodiments, the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC has a purity greater than 30%, 40%, 50%, 60%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, for example, as measured by HPLC. In some embodiments, the purity is less than 30%, 40%, 50%, 60%, 70%, 72.5%, 75%, 77.5%, 80%, 82.5%, 85%, 87.5%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% as specified on page 20 / 54 of the specification, for example, as measured by HPLC.

[0177] In some embodiments, the purity of the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC is greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, or greater than 98%, as determined by size exclusion chromatography (SEC). In some embodiments, the hydrophobic interaction chromatography (HIC) retention time of the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC is greater than 2 minutes, greater than 3 minutes, greater than 4 minutes, or greater than 5 minutes. In some embodiments, the HIC retention time is less than 2 minutes, less than 3 minutes, less than 4 minutes, less than 5 minutes, or less than 6 minutes.

[0178] In some embodiments, the purity of the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC is greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, or greater than 95%.Greater than 96%, greater than 97%, greater than 98%, or greater than 99%, as determined by capillary electrophoresis-sodium dodecyl sulfate (CE-SDS).

[0179] In some embodiments, the main peak of the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC accounts for a proportion of greater than 40%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, or greater than 90% of the total sample amount, as determined by capillary isoelectric focusing (cIEF). In some embodiments, the acidic peak of the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC accounts for a proportion of less than 10%, less than 15%, less than 20%, less than 25%, less than 30%, less than 35%, less than 40%, less than 45%, less than 50%, less than 55%, less than 60%, less than 65%, less than 70%, or less than 75% of the total sample amount, as determined by capillary isoelectric focusing (cIEF).

[0180] In some embodiments, the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC has a tumor growth inhibition rate or percentage (TGI%) greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. In some embodiments, the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC has a tumor growth inhibition percentage less than 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, or 150%. TGI% can be determined, for example, at 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 days after the start of treatment. As used herein, the tumor growth inhibition rate or percentage (TGI%) is calculated using the following formula: TGI (%) = [1 - (Ti - T0) / (Vi - V0)] × 100. Ti is the mean tumor volume in the treatment group on day i. T0 is the mean tumor volume in the treatment group on day 0. Vi is the mean tumor volume in the control group on day i. V0 is the mean tumor volume of the control group on day 0.

[0181] In some embodiments, the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC has a functional Fc region. In some embodiments, the effector function of the functional Fc region is antibody-dependent cell-mediated cytotoxicity (ADCC).In some embodiments, the effector function of the functional Fc region is phagocytosis. In some embodiments, the effector function of the functional Fc region is ADCC and phagocytosis. In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4.

[0182] In some embodiments, the anti-EGFR / HER3 antibody, antigen-binding fragment, or ADC does not have a functional Fc region. For example, the anti-EGFR / HER3 antibody or its antigen-binding fragment is a Fab, Fab', F(ab')2, or Fv fragment. In some embodiments, the anti-EGFR / HER3 antibody or its antigen-binding fragment described herein has a non-effect-functional Fc region. In some embodiments, the Fc is human IgG4 Fc. In some embodiments, the Fc does not have a functional Fc region. For example, the Fc region has LALA mutations (L234A and L235A mutations according to EU numbers) or LALA-PG mutations (L234A, L235A, P329G mutations according to EU numbers).

[0183] The Fc region may be modified in several other ways. For example, cysteine ​​residues can be introduced into the Fc region, thereby enabling the formation of interchain disulfide bonds in this region. The resulting homodimeric fusion protein may have an increased half-life in vitro and / or in vivo.

[0184] In some embodiments, IgG4 has an S228P mutation (EU number). The S228P mutation prevents IgG4 Fab arm exchange in vivo and in vitro.

[0185] In some embodiments, an Fc region with a glycostructure is provided that lacks fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such an Fc region composition may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined, for example, as described in WO 2008 / 077546, by MALDI-TOF mass spectrometry by calculating the average amount of fucose in the glycan chain at Asn297 relative to the sum of all glycan structures (e.g., complex, heterozygous, and high-mannose structures) attached to Asn297. Asn297 refers to the asparagine residue located at approximately position 297 in the Fc region (Eu number of the Fc region residue; or position 314 in the Kabat number); however, due to minor sequence variations in the Fc region sequence, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucoidylated variants can have improved ADCC function. In some embodiments, to reduce glycan heterogeneity, the Fc region of the antibody can be further modified to replace the asparagine at position 297 with alanine (N297A).

[0186] In some embodiments, after purification by protein A-based affinity chromatography and / or size exclusion chromatography, the main peak of HPLC-SEC accounts for at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% of the protein complex described herein.

[0187] In some embodiments, the bispecific anti-EGFR / HER3 antibody described herein has a higher endocytosis rate than the corresponding monoclonal antibody and / or positive control antibody described herein.

[0188] Antibody-Drug Conjugate (ADC)

[0189] The anti-EGFR / HER3 antibody described herein or its antigen-binding fragment may be conjugated to a therapeutic agent (drug). The therapeutic agent may covalently or non-covalently bind to the anti-EGFR / HER3 antibody. In some embodiments, the anti-EGFR / MUC1 antibody is an anti-EGFR / HER3 bispecific antibody. In some embodiments, the bispecific antibody has a co-light chain.

[0190] In some embodiments, the therapeutic agent is a cytotoxic agent or cell inhibitor (e.g., monomethylolpropionate E, monomethylolpropionate F, camptothecin, cytochalasin B, bacitracin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthraxine, maytansine alkaloids (such as DM-1 and DM-4), diketones, mitoxantrone, photomycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and analogues). Useful classes of cytotoxic, cell growth inhibitors, or immunomodulators include, for example, antituberculosis drugs, DNA small groove binders, DNA replication inhibitors, and alkylating agents.

[0191] In some embodiments, the therapeutic agent may include, but is not limited to, cytotoxic agents, such as chemotherapeutic agents, immunotherapeutic agents, antiviral agents, or antibacterial agents. In some embodiments, the therapeutic agent to be conjugated may be selected from, but is not limited to, MMAE (monomethylauristan E), MMAD (monomethylauristan D), or MMAF (monomethylauristan F).

[0192] Specific functional groups and chemical terms are defined below. For the purposes of this invention, the identification of chemical elements is based on the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition, inside cover, and the definition of specific functional groups is generally as described therein. Furthermore, the general principles of organic chemistry, as well as specific functional groups and reactivity, are described in the following literature: Organic Chemistry, Thomas Sorrell, University of [unclear text - likely a journal title or publication].Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[0193] Unless otherwise expressly stated, all ranges referenced herein are included. When listing numerical ranges, the ranges in this specification (pages 22 / 54, 30 CN 122459348 A) should include every numerical value and subrange within the range. For example, "C1-6" includes C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6.

[0194] Any formula of the compounds of this disclosure or of any formula of the compounds described and depicted herein may have one or more chiral (asymmetric) centers. The present invention includes all stereoisomers of any formula of the compounds described or depicted herein. Asymmetric centers present in any formula of the compounds of the present invention or of any formula of the compounds described and depicted herein may have (R) or (S) configurations independently of each other. When the bonds of the chiral carbons in the structural formula are depicted as straight lines, or when the name of the compound does not contain the (R) or (S) chiral name of the chiral carbon, it should be understood that each chiral carbon has both (R) and (S) configurations, and therefore each enantiomer or diastereomer and mixture thereof is included in the formula or name.

[0195] This disclosure includes all possible enantiomers and diastereomers, as well as mixtures of two or more stereoisomers, such as mixtures of enantiomers and / or diastereomers present in various proportions. Thus, the enantiomers of this disclosure include enantiomeric purees, levorotatory and dextrorotatory enantiomers, racemates, and mixtures of two enantiomers in various proportions. If it is a cis / trans isomer, it includes cis and trans and mixtures in various proportions. If desired, the individual stereoisomers can be prepared by separating the mixture by conventional methods, such as chromatography or crystallization, using stereochemical homogeneity.The starting materials are synthesized or synthesized by stereoselectivity. Optionally, derivatization can be performed prior to the separation of stereoisomers. The separation of the stereoisomer mixture can be performed in an intermediate step of the compound synthesis or on the final racemic product. The absolute stereochemistry can be determined by X-ray crystallography analysis of the crystalline product or crystalline intermediate, and if necessary, the crystalline intermediate can be derivatized using a reagent containing a stereocenter of known configuration. Alternatively, the absolute stereochemical structure can also be determined by vibrational circular dichroism (VCD) spectroscopy.

[0196] Unless otherwise stated, the structures described herein also include compounds that differ only in the presence of one or more isotopically enriched atoms, in other words, compounds in which one or more atoms are replaced by atoms having the same atomic number but a different atomic mass or mass number than the dominant atomic mass or mass number in nature. Such compounds are referred to as “isotope variants”. This disclosure is intended to include all pharmaceutically acceptable isotope variants of any formula of the compounds of the present invention or of any formula depicting and describing the compounds. Examples of isotopes suitable for inclusion in the compounds of this invention include, but are not limited to, isotopes of hydrogen such as 2H (i.e., D) and 3H; carbon such as 11C, 13C, and 14C; chlorine such as 36Cl; fluorine such as 18F; iodine such as 123I and 125I; nitrogen such as 13N and 15N; oxygen such as 15O, 17O, and 18O; phosphorus such as 32P; and sulfur such as 35S. Certain isotopic variants of any formula of the compounds disclosed herein, or of any formula of the compounds depicted and described, such as those containing radioactive isotopes, may be helpful in studies of drug and / or substrate tissue distribution. In particular, compounds having the described structures, differing only in the substitution of a heavier isotope, such as replacing hydrogen with deuterium (2H or D), may provide certain therapeutic advantages, such as greater metabolic stability, prolonged in vivo half-life, or reduced dose requirements, and therefore may be used in certain specific situations. The compounds of this disclosure, or isotopic variants of any formula of the compounds described herein, can generally be prepared by techniques known to those skilled in the art, or by processes similar to those described in the appended examples, and synthesized using suitable isotopically labeled reagents instead of previously used unlabeled reagents.

[0197] The compounds provided herein are described with reference to general formulas and specific compounds. Furthermore, the compounds of this disclosure may exist in a variety of different forms or derivatives, all within the scope of this disclosure. These include, for example, pharmaceutically acceptable salts, tautomers, stereoisomers, racemic mixtures, regioisomers, prodrugs, solvated forms, different crystalline or polymorphic forms, and active metabolites, etc.

[0198] As used herein, unless otherwise stated, the term "pharmaceutically acceptable salt" includes a salt that retains the bioavailability of the particular compound in its free acid / base form and has no adverse effects in a biological or other respect. Pharmaceutically acceptable saltsSalts may be included that form with inorganic bases or acids, as well as organic bases or acids. Where the compounds of this disclosure contain one or more acidic or basic groups, this disclosure also includes their corresponding pharmaceutically acceptable salts. Thus, compounds of the present invention containing acidic groups (such as carboxyl groups) can exist in the form of salts and can be used according to the present invention, such as alkali metal salts, alkaline earth metal salts, aluminum salts, or ammonium salts. Further non-limiting examples of such salts include lithium salts, sodium salts, potassium salts, calcium salts, magnesium salts, barium salts, or salts containing ammonia or organic amines such as ethylamine, ethanolamine, diethanolamine, triethanolamine, piperidine, N-methylglutamine, or amino acids. These salts are readily available, for example, by reacting compounds having acidic groups with a suitable base (e.g., lithium hydroxide, sodium hydroxide, sodium propoxide, potassium hydroxide, potassium ethoxide, magnesium hydroxide, calcium hydroxide, or barium hydroxide). Other basic salts of the compounds of this disclosure include, but are not limited to, copper (I), copper (II), iron (II), iron (III), manganese (II), and zinc salts. The compounds disclosed herein contain one or more basic groups, such as protonable groups, may exist in the form of salts, and may be used according to this disclosure as addition salts of inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, hydrogen iodide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, sulfoacetic acid, trifluoroacetic acid, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, carbonic acid, formic acid, propionic acid, pentylamino acid, diethylacetic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, dihydroxynaphthalic acid, mandelic acid, aminosulfonic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, taurocholic acid, glutaric acid, stearic acid, glutamic acid, or aspartic acid, and other acids known to those skilled in the art. The salts formed include hydrochlorides, chlorides, hydrobromates, bromides, iodides, sulfates, phosphates, methanesulfonates, toluenesulfonates, carbonates, bicarbonates, formates, acetates, sulfoacetates, trifluoromethanesulfonates, oxalates, malonates, maleates, succinates, tartrates, malates, bis(hydroxynaphthalate), mandelates, fumarates, lactates, citrates, glutarate, stearates, aspartate salts, and glutamates. Furthermore, the stoichiometric ratio of the salts formed from the compounds of this invention can be an integer multiple or a non-integer multiple of 1.

[0199] The compounds containing basic nitrogen-containing groups in this disclosure can be quaternized using the following formulations: C1-4 alkyl halides, such as methyl, ethyl, isopropyl and tert-butyl chlorides, bromides and iodides; diC1-4 alkyl sulfates, such as dimethyl sulfate, diethyl sulfate and dipentyl sulfate; C10-18 alkyl halides, such as decyl, dodecyl, lauryl...Cl-, tetradecyl and octadecyl chlorides, bromides and iodides; and aryl C1-4 alkyl halides, such as benzyl chloride and phenylethyl bromide.

[0200] If the compounds of this disclosure contain both acidic and basic groups in the molecule, this disclosure also includes, in addition to the salt forms mentioned, an inner salt or betaine (zwitterion). The corresponding salts can be obtained by conventional methods known to those skilled in the art, for example by contacting these salts with organic or inorganic acids or bases in a solvent or dispersant, or by anion or cation exchange with other salts. This disclosure also includes all salts of the compounds of this disclosure that are not suitable for direct use in pharmaceuticals due to low physiological compatibility, but can be used, for example, as intermediates in chemical reactions or for the preparation of pharmaceutically acceptable salts. For a review of more suitable salts, see Stahl and Wermuth, Hand book of Pharmaceutical Salts: Properties, Selection, and Use (Wiley-VCH, 2002).

[0201] The compounds of this disclosure or any formula of the compounds described and depicted herein, and their pharmaceutically acceptable salts, may exist in both insoluble and soluble forms. As used herein, the term "solvent" refers to a molecular complex comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable solvent molecules. For example, the term "hydrate" is used when the solvent is water.

[0202] Pharmaceutically acceptable solvates according to this disclosure may include those in which the crystalline solvent may be substituted with an isotope, such as D2O, d6-acetone, d6-DMSO.

[0203] Linker (Connecting Compound)

[0204] In some embodiments, the therapeutic agent is coupled via a linker (or connecting compound). As used herein, the term "linker" or "linker compound" refers to a compound that can, for example, react with groups of a ligand compound and a therapeutic agent compound, respectively, to link a ligand (antibody, its antigen-binding fragment, or antigen-binding protein construct, as described herein, page 24 / 54, 32 CN 122459348 A (e.g., a bispecific antibody)) and a therapeutic agent (any therapeutic agent described herein) together to form a ligand-drug conjugate.

[0205] In some embodiments, the linker described herein is a compound having the following formula:

[0206] Formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer, or isotopic variant thereof, wherein Q represents a linker portion capable of coupling with a ligand via a bond selected from carbonyl, thioether, amide, disulfide, and hydrazone; and L represents a linker portion capable of connecting Q to a therapeutic agent.

[0207] In some embodiments, the linker portion (Q in Formula (I)) has the following structure: .

[0208] In some embodiments, the linker portion (L in formula (I)) has the following structure: , wherein L1 is a polypeptide residue consisting of 3 to 8 amino acid residues, the polypeptide residue including at least one amino acid residue with a side chain carboxyl group, such as a glutamic acid residue or an aspartic acid residue, wherein "-COOH" represents the carboxyl group of the C-terminal amino acid residue of the polypeptide residue; L2 is a monodentate, bidentate, or tripentate hydrophilic group absent or attached to the side chain carboxyl group of the amino acid residue of polypeptide residue L1, and L2 has the structure NHC(RL2a)(RL2b)(RL2c), wherein RL2a, RL2b, and RL2c are each independently selected from H, -(CH2O)(CH2CH2O)m(CH2)pC(O)OH, and -(CH2O)(CH2CH2O)m(CH2)pC(O)NHR L2d The group consisting of RL2d, wherein RL2d is H or a C1-6 alkyl group optionally substituted with 1 to 6 hydroxyl groups, each m is independently an integer from 0 to 10, preferably 0 to 4, for example 0, 1, 2, 3 or 4, particularly preferably m is 0, each p is independently an integer from 1 to 4, for example 1, 2, 3 or 4; and represents the N-terminal side of the polypeptide residue covalently linked to the linking portion Q.

[0209] In some embodiments, the polypeptide residue L1 is NH-glutamic acid-valine-alanine-COOH. In some embodiments, the hydrophilic group L2 has the following structure: , where “ ” represents the site covalently linked to the polypeptide residue L1, for example, the side chain of the glutamic acid residue in NH-glutamic acid-valine-alanine-COOH.

[0210] In some embodiments, the linker described herein is a compound having the following structure: Specification 25 / 54 pages 33 CN 122459348 A

[0211] CPT-L

[0212] In some embodiments, the linker is a VC linker. For details on the linkers used in ADCs, see Su, Z. et al., "Antibody–drug conjugates: Recent advances in linker chemistry." Acta Pharmaceutica Sinica B (2021), the entire text of which is incorporated herein by reference.

[0213] Therapeutic agents

[0214] In some embodiments, therapeutic agents conjugated with the antibodies or their antigen-binding fragments described herein are discussed below.

[0215] In some embodiments, the therapeutic agents described herein are cytotoxic agents. In some embodiments, the cytotoxic agents are camptothecin compounds, analogs or derivatives thereof. In some preferred embodiments, the camptothecin compound is a compound having the following structure: , wherein X is selected from the group consisting of -CH2-, O and S; and Y is selected from the group consisting of H, D and F.

[0216] In some embodiments, the therapeutic agent is (S)-4-amino-9-ethyl-9-hydroxy-1,9,12,15-tetrahydro-13H-pyrano[3',4':6,7]inzazido[1,2-b]thiarano[4,3,2-de]quinoline-10,13(2H)-dione (CPT-1). The structure of CPT-1 is shown below: .

[0217] CPT-1 Specification 26 / 54 pages 34 CN 122459348 A

[0218] In some embodiments, the therapeutic agent is (S)-4-amino-9-ethyl-9-hydroxy-1,9,12,15-tetrahydro-13H-pyrano[4,3,2-de]pyrano[3',4':6,7]inzazido[1,2-b]quinoline-10,13(2H)-dione (CPT-2). The structure of CPT-2 is shown below: .

[0219] CPT-2

[0220] In some embodiments, the therapeutic agent is CPT3. The structure of CPT-3 is shown below: .

[0221] CPT-3

[0222] In some embodiments, the therapeutic agent is (S)-4-amino-9-ethyl-5-fluoro-9-hydroxy-1,9,12,15-tetrahydro-13H-pyrano[4,3,2-de]pyrano[3',4':6,7]inzizo[1,2-b]quinoline-10,13(2H)-dione (CPT-4). The structure of CPT-4 is shown below: .

[0223] CPT-4

[0224] In some embodiments, the therapeutic agent is auristatin, such as auristatin E (also known in the art as a derivative of dolasstatin-10) or a derivative thereof. For example, olistatin can be an ester formed between olistatin E and a keto acid. For instance, olistatin E can react with acetylbenzoic acid or benzoylvaleric acid to produce AEB and AEVB, respectively. Other typical olistatins include AFP, MMAF, and MMAE. Exemplary synthesis and structures of olistatin are described in U.S. Patent Application Publication No. 2003-0083263, International Patent Publication No. WO 04 / 010957, International Patent Publication No. WO 02 / 088172, and U.S. Patent Nos. 7,498,298, 6,884,869, 6,323,315; 6,239,104; 6,034,065; 5,780,588; 5,665,860; 5,663,149; 5,635,483; 5,599,902; 5,554,725; 5,530,097; 5,521,284; 5,504,191; 5, 410,024; 5,138,036; 5,076,973; 4,986,988; 4,978,744; 4,879,278; 4,816,444; and 4,486,All of these are described in 414, the full text of which is incorporated herein by reference and used for the purposes described herein.

[0225] Studies have shown that olistatin can interfere with microtubule dynamics, as well as cell nuclei and cell division, and has anticancer activity. Olistatin binds to tubulin and can produce cytotoxic or inhibitory effects on cancer cells. Many different detection methods are known in the art for determining whether olistatin or antibody-drug conjugates derived therefrom produce inhibitory or cytotoxic effects on desired cells.

[0226] In some embodiments, the therapeutic agent is a chemotherapeutic agent. Examples of chemotherapeutic agents include alkylating agents (such as thiotepa and cyclophosphamide (CYTOXAN™)); alkyl sulfonates (such as busulfan, indomethacin, and piperazofan); aziridines (such as benzodopa, carboquinone, meturedopa, and uredopa); ethyleneimine and methylmelamines (including hexamethylmelamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide, and trimethylolomelamine); and nitrogen mustards (such as chlorambucil, naphthiamethoxam, cholophosphamide, estradiol, ifosfamide, phenylalanine mustard, dichloromethyldiethylamine, and mechlorethamine oxide). Hydrochlorides, neonitrogen mustard, benzyl mustard cholesterol, prednimustine, trazophosphatide, uracil mustard; nitrosoureas (such as carmustine, chloramphenicol, formustine, lomustine, nimustine, ramustine); antibiotics (such as aclarubicin, actinomycin, atrazosin, azoserine, actinomycin C, chalcogenide, kalabicin, erythromycin, carcinomacin, chromomycin, actinomycin D, daunorubicin, ditocin). Doxorubicin, 6-diazo-5-oxo-L-leucine, epirubicin, isorubicin, idarubicin, metharubicin, mitomycin, mycophenolic acid, nogamycin, oligomycin, pepromycin, potfiromycin, puromycin, triamcinolone acetonide, rodorubicin, streptomycin, streptozotocin, tuberculin, ubenmex, fenestrated sulfadiazine, zoleobacillus; antimetabolites (such as methotrexate and 5-fluorouracil (5-FU)); folic acid analogs (such as folate, methotrexate, pteroxate, trimethoprim); purine analogs (such as fludarabine, 6-mercaptopurine, thioimidapurine, thioguanine); pyrimidine analogs (such as ancitabine, azacitidine, 6-azapyridine, 6-azido ...Uric acid, carmoflurane, cytarabine, dideoxyuridine, deoxyfluorouridine, enoxabin, fluorouridine, 5-FU; androgens (such as calotestosterone, drotalbutone propionate, cyclothiosterol, meandrosten, testrolide); antiadrenergics (such as aminoglutethimide, mitotane, trilosterone); folic acid supplements (such as folinic acid); acetylglucuronolactone; aldophosphamide glycosides. glycoside); aminolevulinic acid; acridine; bestrabucil; bisacodyl; edatraxate; defofamine; colchicine; diacodyl; efornithine; erythritol; etogluconate; gallium nitrate; hydroxyurea; lentinan; chlorphenidate; mitoxantrone; mopiperol; diamine nitridine; pentostatin; phenamet; pirarubicin; podophyllotoxin; 2-ethylhydrazide; procarbazine; PSK7; raszosen; cizonan; germanium spiroamine; cyclohexyl ketone acid; triamine; 2',2',2'-trichlorotriethylamine; ethyl carbamate; vinblastine; dacarbazine; mannomustine; dibromomannitol; dibromoeutherol; piperobromane; cytosine; Arabinoglycosides (“Ara-C”); cyclophosphamides; taxanes (e.g., paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, NJ) and docetaxel (TAXOTERE®, Rhone-Poulenc Rorer, Anthony, France)); chlorambucil; gemcitabine; 6-thioguanine; platinum analogs (such as cisplatin and carboplatin); vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; mitoxantrone (Novantrone); teniposide; donomycin; aminopterin; capecitabine (Xeloda); ibandronate; CPT-11; topoisomerase inhibitors RFS 2000; difluoromethylornithine (DMFO); retinoic acid; esperamycin; capecitabine; and pharmaceutically acceptable salts, acids, or derivatives of any of the foregoing substances. This definition also includes anti-hormonal agents that regulate or inhibit the effects of hormones on tumors, such as anti-estrogens, including, for example, tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazole, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onanasone, and toremifene (Faldon); and anti-androgens, such as flutamide, nilumid, bicalutamide, leuprorelin, and goserelin; and pharmaceutically acceptable salts, acids, or derivatives of any of the foregoing substances. For a detailed description of chemotherapeutic agents, see Example [example missing].For example, US20180193477A1, the entire text of which is incorporated herein by reference.

[0227] Linker-Therapeutic Agent Compound Specification 28 / 54 pages 36 CN 122459348 A

[0228] In some embodiments, a linker (any linker described herein) and a therapeutic agent (any therapeutic agent described herein) may be linked to form a “linker-therapeutic agent” compound.

[0229] In some embodiments, the linker-therapeutic agent compound has the following structure: .

[0230] In some embodiments, the linker-therapeutic agent compound has the following structure: .

[0231] In some embodiments, an antibody (“Ab”), any antibody described herein or an antigen-binding fragment thereof, may be linked to a linker-therapeutic agent compound (any linker-therapeutic agent compound described herein) to generate an antibody-drug conjugate. In some embodiments, the antibody-drug conjugate has the following structure: , where n=1-8. In some embodiments, n=1-8. In some embodiments, n is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8. In some embodiments, n is about 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-8, 3-7, 3-6, 3-5, 3-4, 4-8, 4-7, 4-6, 4-5, 5-8, 5-7, 5-6, 6-8, 6-7, or 7-8. In some embodiments, n is an integer multiple or a non-integer multiple of 1.

[0232] In some embodiments, the anti-EGFR / HER3 antibody is conjugated to a drug via a cleavable linker (e.g., an SPBD linker or a maleimide hexanoyl-valine-citrulline-p-aminobenzyloxycarbonyl (VC) linker). In some embodiments, the anti-EGFR / HER3 antibody is conjugated to a drug via a non-cleavable linker (e.g., an MCC linker formed using SMCC or sulfonyl-SMCC). Those skilled in the art can readily select a suitable linker for a given ADC when considering relevant factors such as the linker site of the anti-EGFR / HER3 antibody, any structural limitations of the drug, and the hydrophobicity of the drug (see, for example, review in Nolting, Chapter 5, Antibody-Drug Conjugates: Methods in Molecular Biology, 2013, Ducry (Ed.), Springer). Many specific linker-toxin combinations have been described, and in some embodiments, they can be used in conjunction with the anti-EGFR / HER3 antibody described herein to prepareADCs. Examples include, but are not limited to, cleavable peptide-based linkers containing aureatine (such as MMAE and MMAF) and camptothecin (such as SN-38, betamethasone, and PBD dimer); non-cleavable MC-based linkers containing aureatine MMAF and MMAE; acid-labile hydrazone-based linkers containing chachomycin and doxorubicin; disulfide-based linkers containing maytansine alkaloids (such as DM1 and DM4); and bis-maleimide-triethylene glycol (BMPEO)-based linkers containing maytansine alkaloid DM1. Some such therapeutic agents and adapters are described, for example, in Peters & Brown, (2015) Biosci.Rep. e00225; Dosio et al., (2014) Recent Patents on Anti-Cancer Drug Discovery 9:35-65; US Patent Publications US 2015 / 0374847 and US20180193477A1; the entire contents of which are incorporated herein by reference.

[0233] Depending on the desired drug and the selected adapter, those skilled in the art may choose a suitable method to couple them together. For example, some conventional coupling methods, such as amine coupling methods, can be used to form the desired drug-adaptor complex, which still contains a reactive group coupled to an anti-EGFR / HER3 antibody by covalent linking. In some embodiments, a drug-maleimide complex (i.e., a maleimide-linked drug) can be used as a payload with a reactive group in this disclosure. In ADC preparation, the most common reactive group capable of bonding with a thiol group is maleimide. In addition, organic bromides and iodides are also frequently used.

[0234] Anti-EGFR / HER3 ADCs can be prepared by one of several methods known in the art, using organic chemical reactions, conditions and reagents known to those skilled in the art (see, for example, Bioconjugate Techniques (G. T. Hermanson, 2013, Academic Press)). For example, conjugation can be performed by (1) reacting the nucleophilic or electrophilic group of the antibody with a divalent linker reagent to form an antibody-linker intermediate Ab-L via covalent bonding, followed by a reaction with an activated drug moiety D; or (2) reacting the nucleophilic or electrophilic group of the drug moiety with a linker reagent to form a drug-linker intermediate DL via covalent bonding, followed by a reaction with the nucleophilic or electrophilic group of the anti-EGFR / HER3 antibody. Conjugation methods (1) and (2) can be used with a variety of antibodies, drug moieties and linkers to prepare the ADCs described herein. Various prepared linkers, linker components and toxins are commercially available or can be prepared using standard synthetic organic chemical techniques. These methods are described, for example, in March's AdvancedOrganic Chemistry (Smith & March, 2006, Sixth Ed., Wiley); Toki et al., (2002) J. Org. Chem. 67:1866-1872; Frisch et al., (1997) Bioconj. Chem. 7:180-186; Bioconjugate Techniques (G. T. Hermanson, 2013, Academic Press); US20210379193A1 and US20180193477A1, all of which are incorporated herein by reference in their entirety. In addition, many pre-formed drug-connectors suitable for reacting with anti-EGFR / HER3 antibodies are commercially available, for example, adapter-toxins including DM1, DM4, MMAE, MMAF, or pyruvic acid SA are available from Creative BioLabs (Shirley, specification 30 / 54 pages 38 CN 122459348 A NY).

[0235] Several specific examples of methods for preparing anti-EGFR / HER3 ADCs are known in the art and described in U.S. Patent Nos. 8,624,003 (one-pot method), 8,163,888 (one-step method), and 5,208,020 (two-step method) and US20180193477A1, all of which are incorporated herein by reference in their entirety. Other methods are known in the art and include those described in Antibody-Drug Conjugates: Methods in Molecular Biology, 2013, Ducry (Ed.), Springer.

[0236] Drug loading is expressed as the number of drug moieties per antibody in the ADC molecule. For some antibody-drug conjugates, drug loading may be limited by the number of attachment sites on the antibody. For example, when cysteine ​​thiol is attached, as in some exemplary embodiments described herein, drug loading may range from 0 to 8 drug moieties per antibody. In some embodiments, higher drug loading, such as p ≥ 5, may cause aggregation, insolubility, toxicity, or loss of cell permeability in some antibody-drug conjugates. In some embodiments, the average drug loading of anti-EGFR / HER3 antibody-drug conjugates ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. In fact, for some antibody-drug conjugates, the optimal ratio of drug moieties per antibody has been shown to be about 4. In some embodiments, the DAR of the anti-EGFR / HER3 ADC composition is about or at least 1.2, 3, 4, 5, 6, 7, or 8. In some embodiments, the average DAR in the anti-EGFR / HER3 ADC composition is about 1 to about 2, about 2 to about 3, about 3 to about 4, about 4 to about 5, about 5 to about 6, about 6 to about 7, or about 7 to about 8.

[0237] In some embodiments, anti-EGFR / HER3 antibody variants are provided having a carbohydrate structure lacking (directly or indirectly) fucose linked to the Fc region. For example, the amount of fucose in such antibodies can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the glycan chain at Asn297 relative to the sum of all sugar structures linked to Asn297 (e.g., complex, heterozygous, and high-mannose structures), as measured by MALDI-TOF mass spectrometry (e.g., as described in WO 2008 / 077546). Asn297 refers to the asparagine residue located at approximately position 297 in the Fc region (Eu number of the Fc region residue; or position 314 in the Kabat number); however, due to minor sequence variations in the antibody, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants may have improved ADCC function. In some embodiments, to reduce glycan heterogeneity, the Fc region of the anti-EGFR / HER3 antibody may be further engineered to replace the asparagine at position 297 (N297A) with alanine.

[0238] In some embodiments, to improve production efficiency by avoiding Fab arm exchange, the Fc region of the anti-EGFR / HER3 antibody or its antigen-binding fragment may be further engineered to replace the serine at position 228 (EU number) of IgG4 with proline (S228P). A detailed description of the S228 mutation can be found in Silva et al., "The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation." Journal of Biological Chemistry 290.9 (2015): 5462-5469, the full text of which is incorporated herein by reference.

[0239] In some embodiments, the methods described herein are intended to prepare bispecific anti-EGFR / HER3 antibodies. Anti-EGFR / HER3 bispecific antibodies can be engineered to maximize the exchange rate between a pair of antibody molecules.The proportion of heterodimers recovered during cell culture is used to prepare the interface. For example, the interface may contain at least a portion of the CH3 domain of the constant antibody domain. In this method, one or more small amino acid side chains at the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). By replacing the large amino acid side chains with smaller amino acid side chains (e.g., alanine or threonine), a compensating “cavity” of the same or similar size as the large side chain is created at the interface of the second antibody molecule. This provides a mechanism that allows the yield of heterodimers to be higher than that of other unwanted end products (such as homodimers). The method is described, for example, in WO 96 / 27011, the entire text of which is incorporated herein by reference. Specification 31 / 54 pages 39 CN 122459348 A

[0240] In some embodiments, a mortar and pestle (KIH) technique may be used, which includes engineered CH3 domains to create “mortars” or “pestle” in each heavy chain to promote heterodimerization. The KIH technique is described, for example, by Xu, Yiren et al., "Production of bispecific antibodies in 'knobs-into-holes' using a cell-free expression system." MAbs. Vol. 7. No. 1. Taylor & Francis, 2015, the full text of which is incorporated herein by reference. In some embodiments, one heavy chain has T366W and / or S354C (pestle) substitutions (EU number), while the other heavy chain has Y349C, T366S, L368A, and / or Y407V (mortar) substitutions (EU number). In some embodiments, one heavy chain has one or more of the following substitutions: Y349C and T366W (EU number). The other heavy chain may have one or more of the following substitutions: E356C, T366S, L368A, and Y407V (EU number). Furthermore, substitutions can be introduced into the hinge regions of both substituted IgGs (-ppcpScp->-ppcpPcp-).

[0241] Recombinant Vectors

[0242] This disclosure also provides recombinant vectors (e.g., expression vectors) comprising isolated polynucleotides disclosed herein (e.g., polynucleotides encoding polypeptides disclosed herein), host cells into which these recombinant vectors are introduced (i.e., vectors containing polynucleotides and / or including polynucleotides), and the production of recombinant antibody polypeptides or fragments thereof by recombination techniques, and the preparation of anti-EGFR / HER3 antibody polypeptides or fragments thereof by recombination techniques.

[0243] As used herein, “vector” is any construct capable of delivering one or more target polynucleotides to a host cell when the vector is introduced into the host cell. “Expression vector” is capable of delivering in a host cell into which the expression vector has been introduced.One or more target polynucleotides are expressed as encoded polypeptides. Thus, in an expression vector, the target polynucleotide is positioned in the vector for expression by operatively linking to regulatory elements (such as promoters, enhancers, and / or poly-A tails) within or near the integration site of the target polynucleotide in the genome of the vector or the host cell, such that the target polynucleotide will be translated in the host cell into which the expression vector is introduced.

[0244] The vector can be introduced into the host cell by methods known in the art, such as electroporation, chemical transfection (e.g., DEAE-glucan), transformation, transfection and infection, and / or transduction (e.g., with recombinant viruses). Therefore, non-limiting examples of vectors include viral vectors (which can be used to generate recombinant viruses), naked DNA or RNA, plasmids, granules, phage vectors, and DNA or RNA expression vectors associated with cationic condensers.

[0245] In some embodiments, the use of a viral expression system (e.g., vaccinia or other poxviruses, retroviruses, or adenoviruses) to introduce the polynucleotides disclosed herein (e.g., polynucleotides encoding polypeptides disclosed herein) may involve the use of a non-pathogenic (defective), replicative virus, or a replication-defective virus may be used. In the latter case, viral replication typically occurs only in complementary viral packaging cells. Suitable systems are disclosed in, for example, Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA 86:317-321; Flexner et al., 1989, Ann. NYAcad Sci. 569: 86-103; Flexner et al., 1990, Vaccine, 8:17-21; U.S. Patent Nos. 4,603,112, 4,769,330 and 5,017,487; WO 89 / 01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91 / 02805; Berkner-Biotechniques, 6:616-627, 1988; Rosenfeld et al., 1991, Science, 252: 431-434; Kolls et al., 1994, Proc. Natl. Acad. Sci. USA, 91:215-219; Kass-Eisler et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11498-11502; Guzman et al., 1993, Circulation, 88:2838-2848; and Guzman et al., 1993, Cir.Res.,73:1202-1207. Techniques for integrating DNA into such expression systems are well known to those skilled in the art. The DNA can also be “naked,” as described, for example, in Ulmer et al., 1993, Science, 259:1745-1749, and Cohen, 1993, Science, 259:1691-1692. The uptake of naked DNA can be increased by coating the DNA on biodegradable beads that are efficiently transported into cells.

[0246] For expression, a DNA insert comprising a polynucleotide encoding an antibody or a polypeptide disclosed herein (pages 32 / 54, CN 122459348 A) can be operatively linked to a suitable promoter (e.g., a heterologous promoter), such as the phage λ PL promoter, E. coli lac, trp and tac promoters, SV40 early and late promoters, and promoters of retroviral LTRs, etc. Other suitable promoters are known to those skilled in the art. The expression construct may also contain transcription initiation and termination sites, and a ribosome binding site for translation within the transcription region. The coding portion of the mature transcript expressed by the construct may include a translation initiation codon at the beginning of the polypeptide to be translated and a stop codon (UAA, UGA, or UAG) at an appropriate position at the end of the polypeptide to be translated.

[0247] As described above, the expression vector may include at least one optional marker. Such markers include dihydrofolate reductase or neomycin resistance genes for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culture in Escherichia coli and other bacteria. Representative examples of suitable hosts include, but are not limited to, bacterial cells such as Escherichia coli, Streptomyces, and Salmonella typhimurium cells; fungal cells such as yeast cells; insect cells such as Drosophila S2 and Fall Armyworm Sf9 cells; animal cells such as CHO, COS, Bowes melanoma, and HK 293 cells; and plant cells. Suitable culture media and conditions for the host cells described herein are known in the art.

[0248] Non-limiting vectors for bacteria include pQE70, pQE60, and pQE-9 obtained from Qiagen; pBS, Phagescript, Bluescript, pNH8A, pNH16a, pNH18A, and pNH46A obtained from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 obtained from Pharmacia. Non-limiting eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, and pSG obtained from Stratagene; and pS, pS, pS, pG44, pXT1, and pSG obtained from Pharmacia.pSVK3, pBPV, pMSG, and pSVL. Other suitable vectors will be apparent to those skilled in the art.

[0249] Suitable non-restrictive bacterial promoters include the Escherichia coli lacI and lacZ promoters, T3 and T7 promoters, gpt promoters, λPR and PL promoters, and trp promoters. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, early and late SV40 promoters, retroviral LTR promoters (such as the Rous sarcoma virus (RSV) promoter), and metallothionein promoters (such as the mouse metallothionein-I promoter).

[0250] In Saccharomyces cerevisiae, many vectors containing constitutive or inducible promoters can be used, such as α-factor, alcohol oxidase, and PGH. For reviews, see Ausubel et al., (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, and Grant et al., Methods Enzymol., 153: 516-544 (1997).

[0251] The construct can be introduced into host cells by calcium phosphate transfection, DEAE-glucan-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. These methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986), the full text of which is incorporated herein by reference.

[0252] The transcription of DNA encoding the disclosed anti-EGFR / HER3 antibody in higher eukaryotes can be increased by inserting an enhancer sequence into the vector. An enhancer is a cis-acting element of DNA, typically about 10-300 bp, which increases the transcriptional activity of the promoter in a given host cell type. Examples of enhancers include the SV40 enhancer located on the late side of the origin of replication at base pairs 100-270, the cytomegalovirus early promoter enhancer, the polyomavirus enhancer located on the late side of the origin of replication, and the adenovirus enhancer.

[0253] To enable the translated protein to be secreted into the endoplasmic reticulum lumen, the periplasmic space, or the extracellular environment, an appropriate secretion signal can be incorporated into the expressed polypeptide. The signal can be an endogenous signal of the polypeptide or a heterologous signal.

[0254] The polypeptide (e.g., an anti-EGFR / HER3 antibody) can be expressed in modified forms, such as fusion proteins (e.g., GST fusion proteins) or with histidine tags, and can include not only secretion signals but also additional heterologous functional regions.For example, regions of additional amino acids (especially charged amino acids) can be added to the N-terminus of a peptide to improve its stability and durability in host cells, during purification, or during subsequent processing and storage. Furthermore, peptide moieties can be added to the peptide to facilitate purification. These regions can be removed prior to the final preparation of the peptide. Adding peptide moieties to peptides to induce secretion or excretion, improve stability, and facilitate purification are conventional techniques well-known in the art.

[0255] This disclosure also provides nucleic acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% identity with any nucleotide sequence described herein, and amino acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% identity with any amino acid sequence described herein.

[0256] This disclosure also provides nucleic acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% homology with any nucleotide sequence described herein, and amino acid sequences having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% homology with any amino acid sequence described herein.

[0257] In some embodiments, this disclosure relates to a nucleotide sequence encoding any peptide described herein or any amino acid sequence encoded by any nucleotide sequence described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30,40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, or 400 amino acid residues.

[0258] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any of the sequences described herein.

[0259] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any of the sequences described herein.

[0260] To determine the percentage of identity between two amino acid sequences or two nucleic acid sequences, these sequences are aligned for optimal comparison purposes (e.g., vacancies may be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment, and non-homologous sequences may be ignored for comparison purposes). The amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). Taking into account the number of vacancies that need to be introduced to achieve optimal alignment of the two sequences and the length of each vacancy, the percentage of identity between the two sequences is a function of the number of common positions shared by the sequences. For example, sequence comparison and determination of the percentage of identity between two sequences can be accomplished using the Blossum 62 scoring matrix, where the vacancy penalty is 12, the vacancy extension penalty is 4, and the frameshift vacancy penalty is 5.

[0261] The percentage of sequence homology (e.g., amino acid sequence homology or nucleic acid homology) can also be determined. How to determine the percentage of sequence homology is known in the art. In some embodiments, conserved amino acid residues with similar physicochemical properties (percentage of homology), such as leucine and isoleucine, can be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include, for example, amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), and amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, hemiacetic acid, etc.).The amino acids having nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids having β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids having aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the percentage of homology is higher than the percentage of identity.

[0262] This disclosure provides one or more nucleic acids encoding any of the polypeptides described herein. In some embodiments, the nucleic acid (e.g., cDNA) comprises a polynucleotide encoding the heavy chain polypeptide described herein. In some embodiments, the nucleic acid comprises a polynucleotide encoding the light chain polypeptide described herein. In some embodiments, the nucleic acid comprises a polynucleotide encoding the scFv polypeptide described herein.

[0263] In some embodiments, the vector may have both of the nucleic acids described herein, wherein the vector encodes the VL and VH regions of HER3 that bind together. In some embodiments, a pair of vectors is provided, wherein each vector comprises one of the nucleic acids described herein, wherein the pair of vectors co-encodes the VL and VH regions of HER3 that bind together.

[0264] In some embodiments, the vector comprises both of the nucleic acids described herein, wherein the vector encodes the VL and VH regions of EGFR that commonly bind. In some embodiments, a pair of vectors is provided, wherein each vector comprises one of the nucleic acids described herein, wherein the pair of vectors commonly encodes the VL and VH regions of EGFR that commonly bind.

[0265] Treatment Methods

[0266] The methods described herein include methods for treating cancer-related conditions. Typically, the methods comprise administering a therapeutically effective amount of the anti-EGFR / HER3 antibody or anti-EGFR / HER3 antibody-drug conjugate described herein to a subject who requires or has been determined to require such treatment.

[0267] As used herein, “treatment” means improvement of at least one symptom of a cancer-related condition. Typically, cancer leads to death; therefore, treatment can increase life expectancy (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 9, 10 years). Applying a therapeutically effective amount of the agents described herein to treat cancer-related conditions will reduce the number of cancer cells and / or alleviate symptoms.

[0268] As used herein, the term “cancer” refers to cells with autonomous growth capacity, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. This term is intended to include all types of cancerous growth or carcinogenic processes, metastatic tissue, or malignant transformation of cells, tissues, or organs, regardless of their histopathological type or stage of invasion. As used herein, the term “tumor” refers to cancer cells, such as clusters of cancer cells. Cancers that can be treated or diagnosed using the methods described herein include a wide variety of cancers.Malignant tumors of organ systems, such as those affecting the lungs, breasts, thyroid, lymph nodes, gastrointestinal tract, and genitourinary tract; and adenocarcinomas, which include malignant tumors such as most colon cancers, renal cell carcinomas, prostate cancers and / or testicular tumors, non-small cell lung cancers, small bowel cancers, and esophageal cancers. In some embodiments, the agents described herein are designed to treat or diagnose cancer in a subject. The term “cancer” is recognized in the art and refers to a malignant tumor of epithelial or endocrine tissue, including respiratory system cancers, gastrointestinal system cancers, genitourinary system cancers, testicular cancers, breast cancers, prostate cancers, endocrine system cancers, and melanomas. In some embodiments, the cancer is renal cancer or melanoma. Exemplary cancers include cancers arising from tissues of the esophagus, cervix, lungs, prostate, breast, head and neck, colon, and ovaries. The term also includes carcinosarcomas, for example, which include malignant tumors composed of carcinomatous and sarcomatous tissues. “Adenocarcinoma” refers to cancer originating from glandular tissue or in which tumor cells form identifiable glandular structures. The term "sarcoma" is recognized in the art and refers to a mesenchymal-derived malignant tumor.

[0269] In some embodiments, the cancer is chemotherapy-resistant cancer.

[0270] In one aspect, this disclosure also provides methods for treating cancer in a subject, methods for reducing the rate of increase in tumor volume in a subject over time, methods for reducing the risk of metastasis, or methods for reducing the risk of additional metastasis in a subject. In some embodiments, the treatment may terminate, slow, delay, or inhibit the progression of cancer. In some embodiments, as described on pages 35 / 54 of CN 122459348 A, the treatment may reduce the number, severity, and / or duration of one or more symptoms of cancer in a subject.

[0271] In one aspect, this disclosure includes a method of administering a therapeutically effective amount of the anti-EGFR / HER3 antibody or anti-EGFR / HER3 antibody drug conjugate of this disclosure to a subject in need, such as a subject who has or has been identified or diagnosed with cancer, the cancer being, for example, a solid tumor, lung cancer (e.g., non-small cell lung cancer, lung adenocarcinoma), gastric cancer, skin cancer, colorectal cancer, breast cancer, head and neck cancer, ovarian cancer, prostate cancer, thyroid cancer, pancreatic cancer, CNS cancer, liver cancer, nasopharyngeal carcinoma, brain cancer, colon cancer, bladder cancer, oral squamous cell carcinoma, cervical cancer, or esophageal cancer. In some embodiments, the cancer is esophageal cancer, colorectal cancer, gastric cancer, breast cancer, endometrial cancer, lung cancer, melanoma, ovarian cancer, bladder cancer, non-Hodgkin's lymphoma, head and neck cancer, pancreatic cancer, and cervical cancer.

[0272] As used herein, the terms “subject” and “patient” are used interchangeably throughout the specification and describe animals (human or non-human) to be treated according to the method of the invention. This invention considers both veterinary and non-veterinary applications. Human patients can be adults or adolescents (e.g., people under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, and...Hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. This includes, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), rabbits, pigs (e.g., pigs, miniature pigs), horses, dogs, cats, cattle, and other domesticated, farm, and zoo animals.

[0273] In some embodiments, the compositions and methods disclosed herein can be used to treat patients at risk of cancer. Cancer patients can be identified using various methods known in the art.

[0274] As used herein, “effective amount” means an amount or dose sufficient to achieve beneficial or desired results, including terminating, slowing, delaying, or inhibiting the progression of a disease (e.g., cancer). The effective amount will vary depending on the age and weight of the subject to be administered, the severity of symptoms, and the route of administration, such as the anti-EGFR / HER3 antibody, the anti-EGFR / HER3 antigen-binding fragment, the anti-EGFR / HER3 antibody drug conjugate, the anti-EGFR / HER3 antibody-encoded polynucleotide, the carrier comprising the polynucleotide, and / or a combination thereof, and therefore can be determined on an individual basis.

[0275] The effective amount may be administered in one or more doses. For example, the effective amount of the anti-EGFR / HER3 antibody, the anti-EGFR / HER3 antigen-binding fragment, or the anti-EGFR / HER3 antibody drug conjugate is an amount sufficient to improve, terminate, stabilize, reverse, inhibit, slow, and / or delay the progression of an autoimmune disease or cancer in a patient, or an amount sufficient to improve, terminate, stabilize, reverse, slow, and / or delay the proliferation of cells (e.g., biopsy cells, any of the cancer cells described herein, or cell lines (e.g., cancer cell lines)) in vitro. As understood in the art, the effective amount of an anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, or anti-EGFR / HER3 antibody drug conjugate can vary depending on, in particular, patient history and other factors such as the type (and / or dosage) of the composition used.

[0276] The effective amount and dosing regimen of the anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, anti-EGFR / HER3 antibody-encoded polynucleotide, anti-EGFR / HER3 antibody drug conjugate, and / or composition disclosed herein can be determined empirically, and such determination is within the scope of the art. Those skilled in the art will understand that the dose that must be administered will vary depending, for example, on the mammal to which the anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, anti-EGFR / HER3 antibody-encoded polynucleotide, anti-EGFR / HER3 antibody drug conjugate, and / or composition disclosed herein will be received, the route of administration, the specific type of antibody, antibody-encoded polynucleotide, antigen-binding fragment, antibody drug conjugate, and / or composition disclosed herein used, and other drugs administered to the mammal.

[0277] The typical daily dose of an effective amount of anti-EGFR / HER3 antibody or anti-EGFR / HER3 antibody conjugate is from 0.01 mg / kg to 100 mg / kg. In some embodiments, the dose may be less than 100 mg / kg, 30 mg / kg, 20 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, or 0.1 mg / kg. In some embodiments, the dose may be greater than 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg, or 0.01 mg / kg. In some embodiments, the dose is about or at least 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.9 mg / kg, 0.8 mg / kg, 0.7 mg / kg, 0.6 mg / kg, 0.5 mg / kg, 0.4 mg / kg, 0.3 mg / kg, 0.2 mg / kg, or 0.1 mg / kg.

[0278] In any of the methods described herein, at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, anti-EGFR / HER3 antibody-pharmaceutical conjugate, or pharmaceutical composition (e.g., any of the anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, or anti-EGFR / HER3 ADC described herein) and optionally at least one additional therapeutic agent may be administered to the subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day, or three times a day).

[0279] In some embodiments, one or more additional therapeutic agents may be administered to the subject before or after administration of at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, anti-EGFR / HER3 antibody pharmaceutical conjugate, or pharmaceutical composition (e.g., comprising any anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 ADC). In some embodiments, administration of one or more additional therapeutic agents and at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 antibody pharmaceutical conjugate to the subject results in...The subjects may have overlapping periods of biological activity of one or more additional therapeutic agents and at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 ADC.

[0280] In some embodiments, at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, anti-EGFR / HER3 antibody-drug conjugate, or pharmaceutical composition (e.g., any one of the anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 ADC described herein) may be administered to the subjects over extended time periods (e.g., over a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years). Skilled medical professionals may use any of the methods described herein to determine the length of the treatment period for diagnosis or to track treatment effectiveness (e.g., to observe at least one symptom of cancer). As described herein, skilled medical professionals may also vary the type and amount (e.g., increase or decrease) of the anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 ADC (and / or one or more additional therapeutic agents) administered to the subject, and may also adjust (e.g., increase or decrease) the dose or frequency of at least one anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding antibody fragment, or anti-EGFR / HER3 ADC (and / or one or more additional therapeutic agents) administered to the subject based on an assessment of treatment effectiveness (e.g., using any of the methods described herein and known in the art).

[0281] In some embodiments, one or more additional therapeutic agents may be administered to the subject. The additional therapeutic agent may include one or more inhibitors selected from the group consisting of: B-Raf inhibitors, HER3 inhibitors, MEK inhibitors, ERK inhibitors, K-Ras inhibitors, c-Met inhibitors, EGFR inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, Akt inhibitors, mTOR inhibitors, PI3K / mTOR dual inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, and isocitrate dehydrogenase 1 (IDH1) and / or isocitrate dehydrogenase 2 (IDH2) inhibitors. In some embodiments, the additional therapeutic agent is an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor (e.g., epacadostat).

[0282] In some embodiments, the additional therapeutic agent may include one or more inhibitors, the one or more inhibitorsThe agent is selected from the group consisting of: HER3 inhibitors, LSD1 inhibitors, MDM2 inhibitors, BCL2 inhibitors, CHK1 inhibitors, hedgehog signaling pathway inhibitors, and selective estrogen receptor degraders (product information, page 37 / 54, CN 122459348 A).

[0283] In some embodiments, additional therapeutic agents may include one or more therapeutic agents selected from the group consisting of: trabectedin, albumin-bound paclitaxel, trebananib, pazopanib, cediranib, palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib. Reolysin, Alimta, Zykadia, Sutent, temsirolimus, axitinib, sorafenib, Votrient, IMA-901, AGS-003, cabozantinib, vinflunine, Hsp90 inhibitors, Ad-GM-CSF, temazolomide, IL-2, IFNa, vinblastine, thalidomide, dacarbazine, cyclophosphamide, lenalidomide, azacytidine, bortezomid, amrubicin, carfilzomib, pralatrexate, and enzastaurin.

[0284] In some embodiments, additional therapeutic agents may include one or more therapeutic agents selected from the group consisting of: adjuvants, TLR agonists, tumor necrosis factor (TNF) α, IL-1, HMGB1, IL-10 antagonists, IL-4 antagonists, IL-13 antagonists, IL-17 antagonists, HVEM antagonists, ICOS agonists, treatments targeting CX3CL1, CXCL9, CXCL10, CCL5, LFA-1 agonists, ICAM1 agonists, and selective protein agonists.

[0285] In some embodiments, the subject is administered carboplatin, albumin-bound paclitaxel, paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI.

[0286] In some embodiments, additional therapeutic agents are anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-LAG-3 antibodies, anti-TIGIT antibodies, anti-CTLA4 antibodies, anti-CD40 antibodies, anti-OX40 antibodies, anti-4-1BB antibodies, anti-TIM3 antibodies, or anti-GITR antibodies.

[0287] Pharmaceutical Compositions and Routes of Administration

[0288] Pharmaceutical compositions comprising at least one (e.g., one, two, three, or four) of the anti-EGFR / HER3 antibodies described herein (e.g., bispecific antibodies), anti-EGFR / HER3 antigen-binding fragments, or anti-EGFR / HER3 antibody pharmaceutical conjugates are also provided herein. Pharmaceutical compositions may be formulated in any manner known in the art.

[0289] Pharmaceutical compositions are formulated to be compatible with their intended routes of administration (e.g., intravenous, intra-arterial, intramuscular, intradermal, subcutaneous, or intraperitoneal). The composition may include a sterile diluent (e.g., sterile water or saline), a fixing oil, polyethylene glycol, glycerol, propylene glycol or other synthetic solvents, an antibacterial or antifungal agent (such as benzyl alcohol or methylparaben, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.), an antioxidant (such as ascorbic acid or sodium bisulfite), a chelating agent (such as ethylenediaminetetraacetic acid), a buffer (such as acetate, citrate or phosphate), and an isotonic agent (such as sugar (e.g., glucose), polyol (e.g., mannitol or sorbitol) or salt (e.g., sodium chloride)), or any combination thereof. Liposome suspensions may also be used as pharmaceutically acceptable carriers (see, for example, U.S. Patent No. 4,522,811). Formulations of the composition may be formulated and encapsulated in ampoules, disposable syringes or multi-dose vials. When needed (e.g., in injectable formulations), appropriate flowability may be maintained by, for example, the use of a coating (such as lecithin) or a surfactant. The absorption of anti-EGFR / HER3 antibodies, anti-EGFR / HER3 antigen-binding fragments, or anti-EGFR / HER3 ADCs can be prolonged by including agents that delay absorption (e.g., aluminum monostearate and gelatin). Alternatively, controlled release can be achieved via implants and microencapsulated delivery systems that may include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza and Nova Pharmaceuticals).

[0290] Compositions containing one or more of the anti-EGFR / HER3 antibodies, anti-EGFR / HER3 antigen-binding fragments, and anti-EGFR / HER3 antibody-drug conjugates described herein can be formulated for parenteral (e.g., intravenous, intra-arterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration in dose units (i.e., physically discrete units containing a predetermined amount of the active compound for ease of administration and dose uniformity).

[0291] The toxicity and efficacy of the composition can be determined in cell cultures or laboratory animals (e.g., monkeys) using standard pharmaceutical methods. The LD50 (the dose that is lethal to 50% of the population) and ED50 (the dose that is therapeutically effective to 50% of the population) can be determined: the therapeutic index is the ratio of LD50 to ED50. Agents exhibiting a high therapeutic index are preferred. When an agent exhibits undesirable side effects, care should be taken to minimize potential harm (i.e., reduce undesirable side effects). Toxicity and efficacy can be determined using other standard pharmaceutical methods.

[0292] Data obtained from cell culture assays and animal studies can be used to formulate appropriate doses of any given agent for use in subjects (e.g., humans). A therapeutically effective amount of an anti-EGFR / HER3 antibody, anti-EGFR / HER3 antigen-binding fragment, or anti-EGFR / HER3 ADC would be the amount used to treat a subject (e.g., a human subject identified as having cancer) for the purpose of killing cancer cells or to treat a subject identified as being at risk of developing the disease (e.g., a subject who previously had cancer but is now cured), reducing the severity, frequency, and / or duration of one or more symptoms of the disease in the subject (e.g., in humans). The effectiveness and dosage of any anti-EGFR / HER3 antibody, its anti-EGFR / HER3 antigen-binding fragment, or anti-EGFR / HER3 ADC described herein can be determined by a healthcare professional or veterinary professional using methods known in the art and by observing one or more symptoms of the disease in a subject (e.g., a human). Certain factors may influence the dosage and duration required for effective treatment of a subject (e.g., the severity of the disease or disorder, previous treatments, the subject's general health condition and / or age, and the presence of other diseases).

[0293] Exemplary doses include milligrams or micrograms of any anti-EGFR / HER3 antibody, its anti-EGFR / HER3 antigen-binding fragment, or anti-EGFR / HER3 ADC per kilogram of subject weight (e.g., about 1 μg / kg to about 500 mg / kg; about 100 μg / kg to about 500 mg / kg; about 100 μg / kg to about 50 mg / kg; about 10 μg / kg to about 5 mg / kg; about 10 μg / kg to about 0.5 mg / kg; or about 0.1 mg / kg to about 0.5 mg / kg). While these doses cover a wide range, those skilled in the art will understand that the potency of therapeutic agents (including antigen-binding protein constructs, antibodies, and their antigen-binding fragments) varies, and effective amounts can be determined by methods known in the art. Typically, a relatively low dose is administered first, and then the primary healthcare professional or veterinary professional (in the case of therapeutic applications) or researcher (when still working in the development phase) may gradually increase the dose until an appropriate response is obtained. Furthermore, it should be understood that the specific dose for any particular subjectThe dosage level will depend on a variety of factors, including the activity of the specific compound used, the subject's age, weight, general health condition, sex and diet, timing of administration, route of administration, excretion rate and half-life of the antibody or antibody fragment in vivo.

[0294] The pharmaceutical composition may be included in a container, package or dispenser along with the instructions for use. This disclosure also provides methods for preparing the anti-EGFR / HER3 antibodies, anti-EGFR / HER3 antigen-binding fragments or anti-EGFR / HER3 ADCs described herein for various uses.

[0295] Examples

[0296] The invention is further described in the following examples, which do not limit the scope of the invention as described in the claims.

[0297] Example 1. Preparation of anti-EGFR / HER3 bispecific antibodies

[0298] The present invention provides bispecific antigen-binding molecules targeting EGFR and HER3. These antigen-binding molecules are referred to below as anti-EGFR / HER3 bispecific antibodies.

[0299] Anti-EGFR antibodies (9F3, VH SEQ ID NO: 41, VL SEQ ID NO: 40; 9D2, VH SEQ ID NO: 42, VL SEQ ID NO: 40 and 9A6, VH SEQ ID NO: 43, VL SEQ ID NO: 40) and anti-HER3 antibodies (1B2, VH SEQ ID NO: 44, VL SEQ ID NO: 40; 3E1, VH SEQ ID NO: 45, VL SEQ ID NO: 40 and 3G6, VH SEQ ID NO: 46, VL SEQ ID NO: 40) can be paired to form bispecific antibodies. Vectors encoding antibody light chains and antibody heavy chains were constructed. CHO-S cells were co-transfected with three vectors, including a first vector encoding the anti-EGFR antibody heavy chain, a second vector encoding the anti-HER3 antibody heavy chain, and a third vector encoding the co-light chain. After 14 days of culture, the cell supernatant was collected and purified by Protein A affinity chromatography. Exemplary bispecific antibodies obtained included 9F3-1B2, 9F3-3E1, 9F3-3G6, 9D2-1B2, 9D2-3E1, 9D2-3G6, 9A6-1B2, 9A6-3E1, and 9A6-3G6.

[0300] Various methods can be used to reduce the chance of mispairing between the two heavy chains. For example, knocks-in-holes mutations can be introduced into the Fc regions of the anti-EGFR arm heavy chain and the anti-HER3 arm heavy chain. For example, in 9F3-1B2, the heavy chain of 9F3 is constant.The region includes a club-shaped mutation, and the heavy chain constant region of 1B2 includes a mortise-shaped mutation. For example, in 9F3-3E1, the heavy chain constant region of 9F3 includes a club-shaped mutation, and the heavy chain constant region of 3E1 includes a mortise-shaped mutation.

[0301] The sequences of the light chain constant region, the heavy chain constant region containing the club-shaped mutation, and the heavy chain constant region containing the mortise-shaped mutation are shown in SEQ ID NO: 47, SEQ ID NO: 48, and SEQ ID NO: 49, respectively.

[0302] Four different reference antibodies were synthesized based on the published amino acid sequence information: Ref1 and Ref2 (specific to EGFR), Ref3 (specific to HER3), and Ref4 (specific to EGFR / HER3) for the following experiments. Specifically, the VH and VL sequences shown in SEQ ID NO: 53-58 were linked to the human IgG1 constant region to form Ref1, Ref2, and Ref3, respectively. The heavy chain and light chain sequences of Ref4 are shown in SEQ ID NO: 59-60.

[0303] Example 2. Cross-species binding activity of anti-EGFR / HER3 bispecific antibody

[0304] CHO-fasEGFR cells, CHO-hHER3 cells, or CHO-fasHER3 cells were seeded in 96-well plates at a density of 5 × 10⁴ cells / well. Anti-EGFR / HER3 bispecific antibody was added to the 96-well plates and incubated at 4°C for 30 min. Subsequently, the cells were incubated with the secondary antibody anti-hIgG-Fc-Alex Flour 647 (RL1-H) (Jackson ImmunoResearch Laboratories, Inc., Cat#: 109-606-170) at 4°C in the dark for 15 min, followed by flow cytometry analysis. Human IgG1 was used as an isotype control (ISO).

[0305] CHO-fasEGFR cells, CHO-hHER3 cells, and CHO-fasHER3 cells were obtained by transfecting CHO-S cells with vectors expressing monkey (Macaca fascicularis) EGFR (fasEGFR, SEQ ID NO: 50), human HER3 (hHER3, SEQ ID NO: 51), and monkey (Macaca fascicularis) HER3 (fasHER3, SEQ ID NO: 52), respectively.

[0306] The test results are shown in the table below. All anti-EGFR / HER3 antibodies can bind to human HER3, monkey HER3, and monkey EGFR.

[0307] Table 1 Specification 40 / 54 pages 48 CN 122459348 A

[0308] Example 3. Endocytosis of anti-EGFR / HER3 bispecific antibodies

[0309] 2.5μg / mL of anti-EGFR antibody, anti-HER3 antibody, or anti-EGFR / HER3 bispecific antibody was added to NCI-H292 or NCI-H226 cells along with pHAb-AffiniPure Fab goat anti-human IgG secondary antibody and incubated for 6 hours. The cells were centrifuged and washed with FACS buffer. MFI was measured by flow cytometry. The endocytosis rate of the antibody was calculated. Human IgG1 protein was used as an isotype control (ISO). The results are shown in the table below. In NCI-H292 and NCI-H226 cells, the endocytosis rate of the anti-EGFR / HER3 bispecific antibody was equal to or higher than that of its parental monoclonal antibody.

[0310] Table 2

[0311] In another experiment, the endocytosis of 9F3-3E1 (2.5 μg / mL) in NUGC-4, A431, HCC827, or SW620 cells was detected, and the results are shown in the table below. 9F3-3E1 exhibited better endocytic activity than the reference antibody Ref4.

[0312] Table 3

[0313] Example 4. Binding affinity of anti-EGFR / HER3 bispecific antibody

[0314] The binding affinity of the anti-EGFR / HER3 bispecific antibody to human EGFR, human HER3, monkey EGFR and monkey HER3 was verified by surface plasmon resonance (SPR) using a Biacore™ (Biacore, Inc., Piscataway NJ) 8K biosensor equipped with a pre-immobilized protein A sensor chip.

[0315] Specifically, hEGFR-His (ACROBiosystems Inc., Cat#: EGR-H5222), hHER3-His (ACROBiosystems Inc., Cat#: ER3-H5223), fasEGFR-His (ACROBiosystems Inc., Cat#: EGR-C52H1), and fasHER3-His (Sino Biological, Inc., Cat#: 90043-K08H) were diluted to 200 nM or 400 nM with 1× HBS-EP+ buffer (pH 7.4) and then injected into the Biacore™ 8K biosensor at a flow rate of 10 μL / min for about 50 seconds to achieve the desired protein density (e.g., about 50 response units (RU) or 200 RU). The purified antibody, prepared in 1× HBS-EP+ buffer (pH 7.4) at a concentration of 2 μg / mL, was then injected at a flow rate of 10 μL / min for 50 seconds. Dissociation was monitored for 400 seconds. After the final injection of each titration, the antibody was diluted with glycine (pH 1.5) at a flow rate of 30 μL / min.The chip was regenerated for 30 seconds at a flow rate of μL / min.

[0316] The data were fitted to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B., 1994, Methods Enzymology 6. 99-110) using Biacore™ 8K evaluation software 3.0 to obtain both the kinetic binding rate (kon) and the dissociation rate (koff). The affinity was derived from the quotient of the kinetic rate constant (KD = koff / kon). As will be understood by those skilled in the art, the same method was used for each test antibody, with appropriate adjustments to parameters (e.g., antibody concentration).

[0317] The antibody test results are shown in the table below. The anti-EGFR / HER3 bispecific antibody showed good binding affinity for human EGFR, monkey EGFR, human HER3, and monkey HER3.

[0318] Table 4, Specification, Pages 42 / 54, 50 CN 122459348 A

[0319] Example 5. Stability of anti-EGFR / HER3 bispecific antibodies

[0320] The buffer for the anti-EGFR / HER3 bispecific antibodies was changed to pH 6.0 (3 mg / mL histidine, 80 mg / mL sucrose, and 0.2 mg / mL Tween 80). The antibodies were loaded into sealed Eppendorf tubes and kept at 40±2°C, 60%±5% RH, and 4±3°C for 7 days, and their thermal stability was evaluated. Alternatively, the bispecific antibodies were loaded into a protein A column and eluted with a buffer of pH 3.5 (0.1 mol / L HAc). Immediately half of the antibody was added to 2M Tris buffer, and the pH was adjusted to 7.5 (Specification, Pages 43 / 54, 51 CN 122459348 A). The remaining half was kept at pH 3.5 for 6 hours, and then the pH was adjusted to 7.5. The diluted antibody was kept in a sealed Eppendorf tube at pH 3.5 ± 0.1, 25 ± 2 °C (hereinafter referred to as pH 3.5) for 6 hours to test its stability at low pH.

[0321] After the above treatment, the following tests were performed: (1) the purity of the antibody was detected by size exclusion high performance liquid chromatography (SEC-HPLC) (represented as the percentage of the main peak area to the total area of ​​all peaks (purity, %)); (2) the hydrophobicity of the antibody was detected by hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) (represented as the retention time of the main peak (HIC, min)); (3) the pI (isoelectric point) and charge variable (represented as the main component, acid) of the antibody were detected by capillary isoelectric focusing (cIEF).(4) Changes in antibody purity under non-reducing (CE-SDS(NR)) or reducing (CE-SDS(R)) conditions were detected by capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) (represented as the percentage of the main peak area to the total area of ​​all peaks (purity, %)); (5) Appearance and presence of visible insoluble matter.

[0322] In the SEC-HPLC experiment, the antibody sample was diluted to 1 mg / mL with purified water and an Agilent 1290 chromatography system (connected to an XBridge protein BEH SEC column (200 Å, Waters Corporation)) was used. The following parameters were used: mobile phase: 0.1 M phosphate buffer (PB) + 10% CAN, pH 7.4; flow rate: 1.8 ml / min; column temperature: 25°C; detection wavelength: 280 nm, 220 nm; injection volume: 10 μL; sample tray temperature: approximately 8°C; run time: 7 minutes.

[0323] In the HIC-HPLC experiment, an Agilent 1260 chromatography system (connected to a ProPac HIC-10 column (4.6 x 250 mm, Thermo Scientific)) was used, and the sample was diluted 10-fold using mobile phase A. The following parameters were used: Mobile phase A: 0.9 M ammonium sulfate, 0.1 M phosphate buffer (PB), 10% acetonitrile pH 6.5; Mobile phase B: 0.1 M phosphate buffer (PB), 10% acetonitrile pH 6.5; Flow rate: 0.8 ml / min; Gradient: 0 min 100% A, 2 min 100% A, 32 min 100% B, 34 min 100% B, 35 min 100% A, and 45 min 100% A; Column temperature: 30 °C; Detection wavelength: 280 nm, 220 nm; Injection volume: 10 μg; Sample tray temperature: approximately 10 °C; Run time: 50 min.

[0324] In the cIEF experiment, the Maurice cIEF method development kit (Protein Simple, Cat#: PS-MDK01-C) was used for sample preparation. Specifically, 8 μL of 30 μg protein sample was mixed with the following reagents from the kit: 1 μL Maurice cIEF pI label-7.05, 1 μL Maurice cIEF pI label-10.10, 35 μL 1% methylcellulose solution, 2 μL Maurice cIEF 500 mM arginine, 1.33 μL amphoteric electrolyte (Pharmalyte pH range 3-10), 6.66 μL amphoteric electrolyte (Pharmalyte pH range 8-10.5), and water (added to a final volume of 100 μL).Imaging capillary isoelectric focusing spectra were generated using the Maurice cIEF box (PS-MC02-C) on a Maurice analyzer (Protein Simple, Santa Clara, CA). The total sample focusing time was 10 minutes. Analysis software installed on the instrument was used to analyze the protein absorbance focused at 280 nm.

[0325] In CE-SDS experiments, for CE-SDS(NR) or CE-SDS(R), Maurice (Protein Simple, Maurice™) and the Maurice CE-SDS Size Application Kit (Protein Simple, Cat#: PS-MAK02-S) were used. In CE-SDS, 30 μL of sample buffer, 30 μL of 30 ug antibody sample, 1.5 μL of 25x internal standard, and 3 μL of 250 nM iodoacetamide (SIGMA, Cat#: 16125) were added to a microcentrifuge tube, followed by centrifugation at 3000 rpm for 1 minute and heating in a 70°C water bath for 10 minutes. The samples were then cooled to room temperature and centrifuged at 10,000 rpm for 3 minutes. The supernatant was then transferred to a 96-well plate and tested in Maurice. The following parameters were used: injection voltage 4.6 kV, injection time 20 seconds, separation voltage 5.75 kV, and separation time 40 minutes.

[0326] Detailed results are shown in the table below. The results show that all anti-EGFR / HER3 antibodies 9F3-3E1, 9D2-1B2, 9A6-3E1, and 9A6-3G6 have good stability and physicochemical properties.

[0327] Table 5 Specification 44 / 54 pages 52 CN 122459348 A

[0328] In another experiment, further developmental analyses of the anti-EGFR / HER3 bispecific antibodies were performed. Specifically, the following tests were performed: (1) observing the appearance of the solution and the presence of visible insoluble matter; (2) detecting the specificity of the antibody using cross-interaction chromatography (CIC) (expressed as retention time (CIC, min)); (3) detecting the colloidal stability of the antibody using vertical single-layer chromatography (SMAC) (expressed as retention time (SMAC, % / min)); (4) detecting the thermal stability of the antibody using the UNcle system (expressed as melting temperature (Tm) and aggregation temperature (Tagg)); and (5) detecting the purity of the antibody using hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) (expressed as retention time of the main peak (HIC, min)).

[0329] In the CIC analysis, human polyclonal IgG (Sigma, Cat#: I4506) was coupled to HiTrap NHS activated resin (GE Healthcare, Cat#:17-0716-01), and then the CIC column was prepared by passivation with ethanolamine according to the published procedure. The column was then connected to an Agilent 1260 chromatography system and run at 0.1 mL / min using 1× PBS as the mobile phase until a flat baseline was reached. Then 10 μg of antibody in 1 mg / mL PBS solution was injected. Peak retention times on the column were monitored at 280 nm and 220 nm; run time: 50 min.

[0330] In SMAC analysis, the Zenix column (4.6 mm × 30 cm, Sepax, Cat#: 213300-4630) was connected to the column oven and the appropriate tubing was placed in the mobile phase. The column was equilibrated with mobile phase buffer at a flow rate of 0.350 mL / min for 60 min. The antibody (2 μg) was loaded into the injection sequence. Mobile phase: 150 mM sodium phosphate, pH 7.0; flow rate: 0.35 mL / min; run time: 25 minutes; column temperature: 30°C; detection wavelength: 280 nm, 220 nm.

[0331] In the UNcle experiment, 8 μL of protein sample was loaded into a uni tube, and the system was run at a heating rate of 1 °C / min at a thermal temperature of 25 °C to 95 °C. Particle size and polydispersity were detected by dynamic light scattering (DLS) before heating. Protein stability was characterized by differential scanning spectral fluorescence (DSF), static light scattering (SLS), and dynamic light scattering (DLS).

[0332] In the HIC experiment, an Agilent 1260 chromatography system (connected to a ProPac HIC-10 column (4.6 x 100 mm 5 μm)) was used, and the sample was diluted 10-fold using mobile phase A. The following parameters were used: Mobile phase A: 0.9 M ammonium sulfate, 25 M phosphate buffer (PB), pH 7.0; Mobile phase B: 25 M phosphate buffer (PB), pH 7.0; Flow rate: 1.0 mL / min; Gradient: 0 min 100% A, 2 min 100% A, 5 min 50% B, 25 min 100% B, 28 min 100% B, 29 min 100% A and 35 min 100% A; Column temperature: 30℃; Detection wavelength: 280 nm, 220 nm; Injection volume: 20 μg; Run time: 35 min. This experiment was named HIC02.

[0333] In another HIC experiment, an Agilent 1260 chromatography system (connected to a Proteomix HIC-Phenyl-NP5 column (4.6 x 100 mm 5 μm)) was used, and the sample was diluted 10-fold using mobile phase A. Use the following parameters: Mobile phase A: 0.9g (Instructions for use, pages 45 / 54, 53, CN 122459348 AM, ammonium sulfate, 25g).25 M phosphate buffer (PB), pH 7.0; Mobile phase B: 25 M phosphate buffer (PB), pH 7.0; Flow rate: 0.8 mL / min; Gradient: 0 min 100% A, 2 min 100% A, 32 min 100% B, 34 min 100% B, 35 min 100% A and 45 min 100% A; Column temperature: 30℃; Detection wavelength: 280 nm, 220 nm; Injection volume: 20 μg; Run time: 35 min. This experiment was named HIC03.

[0334] Detailed results are shown in the table below. The results show that the anti-EGFR / HER3 antibody 9F3-3E1 has good stability and physicochemical properties.

[0335] Table 6

[0336] In another experiment, 9F3-3E1 was packed in sealed Eppendorf tubes and kept at 25℃ for 30 days, and its exploitability was evaluated.

[0337] Detailed results are shown in the table below. The results showed that the anti-EGFR / HER3 antibody 9F3-3E1 had good stability and physicochemical properties.

[0338] Table 7

[0339] After the above treatment, the binding activity of 9F3-3E1 with NUGC-4 cells was detected by flow cytometry. The antibody concentration fitting curve was plotted using MFI values. The EC50 value was determined. The test results are shown in the table below. There was no significant change in binding activity after different treatments.

[0340] Table 8

[0341] In another experiment, the binding activity of 9F3-3E1 with NUGC-4 cells was detected by flow cytometry. The antibody concentration fitting curve was plotted using MFI values. The EC50 value was determined. The test results are shown in the table below. There was no significant change in binding activity after different treatments.

[0342] Table 9

[0343] Example 6. Anti-EGFR / HER3 Antibody-Drug Conjugates (ADCs)

[0344] Each purified antibody (9F3, 9D2, 9A6, 1B2, 3E1, 3G6, 9F3-3E1, 9D2-1B2, 9A6-1B2, 9A6-3E1, or 9A6-3G6) was conjugated to MMAE (monomethylaurestatin E) via a maleiminohexanoyl-valine-citrulline-p-aminobenzyloxycarbonyl (VC) linker. For the name of the antibody-drug conjugate, "MMAE" was simply added after the antibody name. For example, if 9F3-3E1 was conjugated to MMAE, it was named 9F3-3E1-MMAE. Antibody drug package inserts generated using a similar method (pages 46 / 54, CN 122459348 A) also include Ref1-MMAE, Ref2-MMAE, and Ref3-MMAE. For the isotype control, human IgG1 is conjugated with MMAE to form ISO-MMAE. The conjugation of the antibody and drug molecule was detected using HIC-HPLC. Results showed that the drug-antibody ratio of each ADC was...The (DAR) is approximately 4.

[0345] In another example, the purified antibody is also conjugated to CPT-1, CPT-2, CPT-3, or CPT-4 via the CPT-L linker. For the name of the ADC, CPTx is simply added after the antibody name. For example, if 9F3-3E1 is conjugated to CPT-1, it is named 9F3-3E1-CPT1. As another example, if 9F3-3E1 is conjugated to CPT-2, it is named 9F3-3E1-CPT2. Antibody-drug conjugates generated by a similar method also include Ref4-CPT2. For the isotype control, human IgG1 is conjugated to CPT-2 to form ISO-CPT2. The conjugation of the antibody to the drug molecule is detected using MS (mass spectrometry). MS results indicate that the drug-antibody ratio (DAR) of the ADC is approximately 8.

[0346] For reference purposes, Ref3 is conjugated to Dxd via the GGFG linker to form Ref3-Dxd, which has a DAR of approximately 4.

[0347] Example 7. Antitumor Activity in a NUGC-4 Xenograft Model

[0348] The effect of ADC on tumor growth in vivo was tested in a NUGC-4 xenograft model of gastric cancer. Specifically, approximately 5 × 10⁶ NUGC-4 cells were subcutaneously injected into B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). The expression levels of EGFR and HER3, as measured by RNAseq, were 8.58 and 154.99, respectively. When the tumor volume of the mice reached approximately 200 mm³, the mice were randomly assigned to different groups (6 mice in each group) according to the tumor volume. Subsequently, mice were administered phosphate-buffered saline (PBS), ISO-MMAE, Ref1-MMAE, Ref3-MMAE, 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, or 9D2-1B2-MMAE via intravenous injection (i.v.). Administration was once weekly (twice a week).

[0349] Tumor volume was measured twice weekly, and mouse weight was recorded. Mice were euthanized when their tumor volume reached 3000 mm³.

[0350] The lengths of the long and short axes of the tumor were measured, and tumor volume was calculated using the following formula: 0.5 × (long axis) × (short axis)². Tumor growth inhibition (TGI) was calculated using the following formula: TGI (%) = [1 - (Ti - T0) / (Vi - V0)] × 100. Ti is the average tumor volume of the treatment group on day i. T0 represents the mean tumor volume in the treatment group on day 0. Vi represents the mean tumor volume in the control group on day i. V0 represents the mean tumor volume in the control group on day 0. Statistical analysis was performed using a t-test. P < 0.0.05 is the threshold for significant difference.

[0351] As shown in Figure 4, all five anti-EGFR / HER3 bispecific ADCs (G5-G9) showed better antitumor activity than the positive controls Ref1-MMAE (G3) and Ref3-MMAE (G4) in the gastric cancer model.

[0352] Example 8. Antitumor activity in NCI-H292 xenograft model

[0353] The effect of ADCs on tumor growth in vivo was tested in a lung cancer NCI-H292 cell xenograft tumor model. Specifically, approximately 5 × 10⁶ NCI-H292 cells were subcutaneously injected into B-NDG mice. The expression levels of EGFR and HER3, as measured by RNAseq, were 55.75 and 4.33, respectively. When the tumor volume of the mice reached approximately 200 mm³, the mice were randomly assigned to different groups (6 mice per group) according to the tumor volume. Subsequently, mice were administered PBS, ISO-MMAE, Ref1-MMAE, Ref3-MMAE, 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, or 9D2-1B2-MMAE via intravenous (iv) injection. Dosing was administered once weekly (twice a week).

[0354] Tumor volume was measured twice weekly. Figure 5 shows the tumor volume measurements, where all anti-EGFR / HER3 ADCs exhibited significant tumor suppression. The TGI% (e.g., day 27) in groups G5-G9 was higher than that in controls G2 and G4, indicating that 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, and 9D2-1B2-MMAE had good tumor suppression effects in the lung cancer model.

[0355] Example 9. Antitumor activity in a patient-derived xenograft model of gastric cancer. 47 / 54 pages. 55 CN 122459348 A

[0356] The effect of ADC on in vivo tumor growth was tested in a patient-derived xenograft (PDX) model of gastric cancer. Immunohistochemical staining of patient-derived gastric tumor fragments showed that the tumor fragments were tissues with high co-expression of EGFR and HER3. Specifically, a patient-derived gastric tumor fragment (2 mm × 2 mm × 2 mm) was implanted into the right back of B-NDG mice. When the tumor volume of the mice reached approximately 250 mm3, the mice were randomly divided into groups (6 mice per group) according to the tumor volume. Subsequently, PBS, ISO-MMAE, Ref3-MMAE, 9A6-3E1-MMAE, and 9A6-3G6-MMAE were administered to the mice via intravenous injection (iv).MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, or 9D2-1B2-MMAE. Administration frequency was once weekly (twice in total).

[0357] Tumor volume was measured twice weekly. As shown in Figure 6, the tumor volume in the G3-G8 treatment groups was smaller than that in the control groups G1 and G2. The results also showed that all five anti-EGFR / HER3 ADCs (G4-G8) exhibited better anti-tumor activity than the positive control Ref3-MMAE (G3). Specifically, on day 21, the TGI% of groups G4 to G8 were 86.2%, 86.4%, 85.4%, 87.2%, and 87.4%, respectively, while the value of group G3 was lower at 68.2%, indicating that 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, and 9D2-1B2-MMAE had good tumor-suppressive effects in the gastric cancer model.

[0358] In another similar experiment, PBS, Ref2-MMAE, Ref3-Dxd, 9A6-3E1-CPT2, 9A6-1B2-CPT2, 9F3-3E1-CPT2, or 9F3-1B2-CPT2 were administered to PDX model mice with gastric cancer via intravenous injection (i.v.). The administration frequency was once a week, except for Ref3-Dxd, all were administered twice. The results are shown in Figure 7. In Groups G1 and G3, mice were euthanized when their tumor volume reached 3000 mm3 on day 11 after grouping. In addition, compared with the positive controls Ref2-MMAE and Ref3-Dxd, 9A6-3E1-CPT2, 9A6-1B2-CPT2, 9F3-3E1-CPT2 and 9F3-1B2-CPT2 showed better tumor suppression effects.

[0359] Example 10. Antitumor activity in a colorectal cancer PDX model

[0360] The in vivo antitumor activity of ADCs was tested in a colorectal cancer PDX model with high EGFR / HER3 expression. Specifically, a fragment of colorectal cancer tumor (2 mm × 2 mm × 2 mm) derived from a patient was implanted into the right back of B-NDG mice. When the tumor volume in mice reached approximately 250 mm3, the mice were randomly assigned to different groups (5 mice per group) based on the tumor volume. Subsequently, PBS, ISO-MMAE, Ref2-MMAE, 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, or 9D2-1B2-MMAE were administered intravenously (iv). Tumor volume was measured twice weekly.

[0361] As shown in Figure 8, 9A6-3E1-MMAE, 9A6-3G6-MMAE, 9A6-1B2-MMAE, 9F3-3E1-MMAE, and 9D2-1B2-MMAE exhibited better antitumor activity than the positive control Ref2-MMAE.

[0362] In a similar experiment, PBS, ISO-CPT2, Ref2-MMAE, Ref3-Dxd, 9A6-3E1-CPT2, 9A6-1B2-CPT2, 9F3-3E1-CPT2, or 9F3-1B2-CPT2 were administered intravenously (i.v.) to PDX model mice with colorectal cancer. Tumor volume was measured twice weekly. The results are shown in Figure 9, where all four anti-EGFR / HER3 bispecific ADCs exhibited better antitumor activity than the positive controls Ref2-MMAE and Ref3-Dxd.

[0363] In another similar experiment, PBS (G1), Ref2-MMAE (G2), Ref3-Dxd (G3), Ref4-CPT2 (G4 and G5), 9F3-3E1-CPT2 (G6 and G7), 9F3-CPT2 (G8), 3E1-CPT2 (G9), or a combination of 9F3-CPT2 and 3E1-CPT2 (G10) were administered intravenously (iv) to PDX model mice with colorectal cancer. Tumor volume was measured twice weekly. The tumor volumes of mice treated with ADC or PBS are shown in Figure 10. Compared with the control group G1, the treatment groups (G2-G10) showed different tumor suppression effects. Among the treatment groups, the 6 mg / kg 9F3-3E1-CPT2 treatment group (G7) showed the best tumor suppression effect, followed by the parental monoclonal antibody ADC treatment groups (G8 and G9) and the positive control group (G2-G5). Furthermore, 9F3-3E1-CPT2 exhibited a dose-dependent tumor suppression effect.

[0364] In another similar experiment, PBS (G1), ISO-MMAE (G2), 9F3-3E1-MMAE (G3), 9F3-MMAE (G4), or 3E1-MMAE (G5) were administered intravenously (iv) to PDX model mice with colorectal cancer. Tumor volume was measured twice weekly. The tumor volumes of mice treated with ADC or PBS in different groups are shown in Figure 13. Compared with the control groups G1 and G2, the treatment groups (G3-G5) showed different tumor suppression effects. Among the treatment groups, the 9F3-3E1-MMAE treatment group (G3) showed better tumor suppression than the parent monoclonal antibody ADC treatment groups (G4 and G5), while also exhibiting a synergistic effect.

[0365] In another similar experiment, PBS (G1) was administered to a colorectal cancer PDX model mouse via intravenous injection (iv).Ref2-MMAE (G2), Ref3-Dxd (G3), Ref4-CPT2 (G4 and G5), 9F3-3E1-CPT2 (G6 and G7). Tumor volume was measured twice weekly. The tumor volumes of mice treated with ADC or PBS in different groups are shown in Figure 14. Compared with the control group G1, the treatment groups (G2-G7) showed different tumor inhibition effects. Among the treatment groups, the 6 mg / kg 9F3-3E1-CPT2 treatment group (G7) showed the best tumor inhibition effect compared with the positive control group (G2-G5). In addition, 9F3-3E1-CPT2 showed a dose-dependent tumor inhibition effect.

[0366] Example 11. Antitumor activity in a lung cancer patient-derived xenograft model

[0367] The effect of ADC on in vivo tumor growth was tested in a lung cancer patient-derived xenograft model. Immunohistochemical staining of patient-derived lung tumor fragments showed that the tumor fragments were tissues with high EGFR expression and low HER3 expression. Specifically, a lung tumor fragment (2 mm × 2 mm × 2 mm) derived from the patient was implanted into the right back of B-NDG mice. When the tumor volume in the mice reached approximately 200 mm3, the mice were randomly divided into groups (5 mice per group) according to the tumor volume. Subsequently, the mice were administered PBS (G1), Ref2-MMAE (G2), Ref3-Dxd (G3), 9A6-3E1-CPT2 (G4), 9A6-1B2-CPT2 (G5), 9F3-3E1-CPT2 (G6), or 9F3-1B2-CPT2 (G7) via intravenous injection (i.v.).

[0368] The tumor volumes of the different groups of mice are shown in Figure 11. 9A6-3E1-CPT2 (G4), 9A6-1B2-CPT2 (G5), 9F3-3E1-CPT2 (G6), or 9F3-1B2-CPT2 (G7) achieved better results than the positive control group (G2 or G3).

[0369] In another similar experiment, based on similar molar amounts, PBS (G1), Ref2-MMAE (G2), Ref3-Dxd (G3), Ref4-CPT2 (G4), or 9F3-3E1-CPT2 (G5) were administered intravenously (iv) to lung cancer PDX model mice, but the dosage of G3 was doubled due to the weaker toxicity of Dxd. Tumor volume was measured twice a week. The tumor volumes of mice in different groups treated with ADC or PBS are shown in Figure 12. Compared with the positive controls Ref2-MMAE, Ref3-Dxd, and Ref4-CPT2, 9F3-3E1-CPT2 showed the best tumor inhibition effect.

[0370] Example 12. The effect of anti-EGFR / HER3 antibody and its ADC in blocking ligand-receptor binding

[0371] The effect of anti-EGFR / HER3 antibody or anti-EGFR / HER3 ADC on the binding of His-labeled human NRG1 (hNRG1-His, ACROBiosystems Inc., Cat#: NR1-H5246) to human HER3 was detected by flow cytometry using NUGC-4 cells.

[0372] NUGC-4 cells were seeded at 2×10⁵ cells / well in 96-well plates. 50 µL of Fixable Viability Dye eFluor™ 506 (eBioscience, Cat#: 65-0866-14) was added to each well and incubated at 2–8°C in the dark for 30 minutes. After washing with PBS, 50 µL of Human TruStrain FcX (Biolegend, Cat#: 422302) was added to each well and incubated at room temperature in the dark for 15 minutes. After washing with PBS, 50 µL of serially diluted test samples (maximum concentration 100 ug / mL) were added to each well of a 96-well plate, followed by 50 µL of hNRG1-His at a final concentration of 50 ng / mL. The plates were incubated at 2–8°C in the dark for 30 minutes, and then washed twice with PBS. Cells were incubated with secondary antibody (APC anti-His labeled antibody, (BioLegend, Cat#: 362605)) at 2–8°C in the dark for 30 minutes, followed by flow cytometry analysis.

[0373] Geometric mean fluorescence intensity (gMFI) was measured. A fitted curve was obtained with antibody concentration (µg / mL) as the X-axis and NRG1 percentage as the Y-axis. The percentage of NRG1 binding (%) = (gMFI value of the corresponding well - gMFI value of the secondary antibody control well) / (gMFI value of the reference well - gMFI value of the secondary antibody control well) × 100%, where the reference well contains only NRG1 and no sample, the secondary antibody control well contains only secondary antibody, and the corresponding well contains NRG1 and different concentrations of sample. The IC50 value was determined.

[0374] The results are shown in the table below. 9F3-3E1 and 9F3-3E1-CPT2 can inhibit the binding of NRG1 to NUGC-4 cells, indicating that the above anti-EGFR / HER3 antibody and anti-EGFR / HER3 ADC can block the binding of NRG1 to HER3.

[0375] Table 10 Specification 49 / 54 pages 57 CN 122459348 A

[0376] In another similar experiment, the blocking effect of anti-EGFR / HER3 antibody or anti-EGFR / HER3 ADC on the binding of His-labeled human EGF (hEGF-His, ACROBiosystems Inc., Cat#: EGF-H52H3) to human EGFR was detected by flow cytometry using NCI-H1975 cells.

[0377] The results showed that 9F3-3E1 and 9F3-3E1-CPT2 could inhibit the binding of EGF to NCI-H1975 cells, indicating that the above-mentioned anti-EGFR / HER3 antibody and anti-EGFR / HER3 ADC could block the binding of EGF to EGFR (data not shown).

[0378] Example 13. Blocking effect of anti-EGFR / HER3 antibody and ADC on EGFR / HER3 signal transduction

[0379] The blocking effect of anti-EGFR / HER3 antibody and its ADC on NRG1 or EGF-induced signal transduction was detected by Western blotting.

[0380] Specifically, NCI-H1975 cells were seeded at 2×106 cells / well in a 96-well plate. 500 µL of test sample with a final concentration of 100 µg / mL was added to the 96-well plate and incubated for 60 minutes. Add 250 µL of NRG1 (ACROBiosystems Inc., Cat#: C1572P1-23CWW1-1HT) or EGF (ACROBiosystems Inc., Cat#: EGF-H52H3) to each well to a final concentration of 100 ng / mL and incubate for 5 minutes. Collect cells into 2 mL centrifuge tubes and centrifuge at 500 × g for 5 minutes at 4°C, discarding the supernatant. Add 100 μL of RIPA lysis buffer to each tube and lyse on ice for 30 minutes. Centrifuge the tubes at 12000 rpm for 10 minutes at 4°C and collect the supernatant, which is the total protein solution. Determine protein concentration using a BCA protein assay kit (Beyotime, Cat#: P0010). Add 5x reduction sample buffer to the protein solution, then denature the protein solution in a metal bath for 10 minutes. Detect the expression of phosphorylated and total HER3, as well as phosphorylated and total MAPK, by Western blotting.

[0381] The fluorescence intensity of each sample was calculated. Relative intensity (%) = target fluorescence intensity / reference (e.g., GAPDH or β-tubulin) fluorescence intensity × 100%.

[0382] The results are shown in Figures 15-17. The pEGFR, pHER3, and pMAPK levels in the 9F3-3E1 and 9F3-3E1-CPT2 groups were reduced, indicating that the above-mentioned anti-EGFR / HER3 antibody and anti-EGFR / HER3 ADC can block EGF-induced EGFR signaling and NRG1-induced HER3 signaling.

[0383] Example 14. Developability assessment of anti-EGFR / HER3 ADC

[0384] 9F3-3E1-CPT2 was placed in sealed Eppendorf tubes and kept at 40°C or 25°C for 7 days, and its developability was assessed by SEC-HPLC, CE-SDS(NR), and CE-SDS(R) tests. Detailed results are shown in the table below. The results show that the anti-EGFR / HER3 ADC9F3-3E1-CPT2 exhibits good stability.

[0385] Table 11

[0386] After the above treatment, the binding activity of 9F3-3E1-CPT2 with EGFR / HER3 antigen was detected by ELISA. An antibody concentration fitting curve was plotted using optical density values. The EC50 value was determined. The test results are shown in the table below. There was no significant change in binding activity after different treatments.

[0387] Table 12 Specification 50 / 54 pages 58 CN 122459348 A

[0388] After the above treatment, the cell-killing activity of 9F3-3E1-CPT2 was detected using HCC827 cells. Specifically, HCC827 cells were seeded in 96-well plates at a density of 3×103 cells / well. Samples treated under different conditions were serially diluted 4-fold starting from a concentration of 400 nM and then added to 96-well plates. After incubation, the plates were centrifuged for 5 minutes, and the culture supernatant was discarded. 100 μL of Vazyme Biotech Cell Counting-Lite 2.0 Luminescent Cell Viability Assay reagent (Vazyme, Cat#: DD1101-02) was added to the corresponding wells and incubated at room temperature in the dark for 10 minutes. Cell viability was then measured using a microplate reader.

[0389] Antibody concentration fitting curves were plotted using cell viability percentages. The IC50 value was determined. The test results are shown in the table below. There was no significant change in cell killing activity after different treatments.

[0390] Table 13

[0391] In another experiment, anti-EGFR / HER3 ADC 9F3-3E1-CPT2 was oxidized with AAPH (2,2'-azobis(2-methylpropanediamine) dihydrochloride) or TBHP (tert-butyl hydrochloride) for 6 hours or 24 hours, respectively, and its exploitability was evaluated by SEC-HPLC, CE-SDS(NR) and CE-SDS(R) tests.

[0392] Detailed results are shown in the table below. The results showed that the anti-EGFR / HER3 ADC 9F3-3E1-CPT2 had good stability after oxidation treatment.

[0393] Table 14

[0394] After the above treatment, the binding activity of 9F3-3E1-CPT2 to EGFR / HER3 antigen was detected by ELISA. The test results are shown in the table below. The binding activity did not change significantly after different treatments.

[0395] Table 15 Specification 51 / 54 pages 59 CN 122459348 A

[0396] After the above treatment, the cell-killing activity of 9F3-3E1-CPT2 was detected by HCC827 cells. The test results are shown in the table below. The cell-killing activity did not change significantly after different treatments.

[0397] Table 16

[0398] Example 15.Pharmacokinetic Characteristics

[0399] The pharmacokinetic clearance of the anti-EGFR / HER3 ADC was determined in C57BL / 6 mice. Specifically, mice were divided into four groups (n=6 per group) and administered 9F3-3E1-CPT2 (G1, 3 mg / kg; G2, 10 mg / kg) or Ref4-CPT2 (G3, 4 mg / kg; G4, 12 mg / kg) intravenously. Blood samples were collected 3 days before administration and 15 minutes, 1 day, 3 days, 7 days, 10 days, 14 days, and 21 days after administration.

[0400] Serum levels of the antibody and ADC were determined using a sandwich ELISA. In short, goat anti-human IgG (H+L) (Jackson ImmunoResearch Inc., Cat#: 109-005-088) or anti-DXD mIgG (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: BCG108501) was diluted to a final concentration of 2000 ng / mL, and 100 µL was added to each well of a 96-well plate. The plate was then incubated overnight at 2–8°C. After incubation, the plate was washed four times with PBS-T buffer (PBS supplemented with Tween™ 20). Unbound areas were blocked with 2% BSA (bovine serum albumin) at 37°C for 2 hours. After washing, 100 µL of sample was added to each well. The wells were sealed and incubated at 37°C for 1 hour. After washing, Peroxidase AffiniPure F(ab')2 Fragment Goat Anti-Human IgG, Fcγ fragment specific (Jackson ImmunoResearch Inc., Cat#: 109-036-098) or Anti-Kappa light chain-HRP (Abcam, Cat#: ab202549) was added at 100 µL / well to the corresponding wells and incubated at 37°C for 1 hour. After washing, tetramethylbenzidine (TMB) solution was added at 100 µL / well as substrate to a 96-well plate. After incubation at room temperature in the dark, 100 µL of stop solution (Beyotime, Cat#: P0215) was added to each well. The luminescence signal of the plate was measured at 450 nm and 630 nm. A standard curve with four parameters was constructed using the absorbance values ​​and corresponding concentrations of calibration samples prepared with each test product. The antibody or ADC concentration for each serum sample was calculated using the standard curve. A drug concentration-time curve was established using the sample concentrations calculated at each time point. (Instructions for Use, pages 52 / 54, 60 CN 122459348 A) Phoenix™ WinNolin8.3 Pharmacokinetic parameters (i.e., T1 / 2, Cmax, AUC0-21 days, and CL) were calculated. The results are shown in the table below. The results indicate that the binding of the drug molecule does not affect the in vivo pharmacokinetic clearance of the bispecific antibody.

[0401] Table 17

[0402] In another experiment, the pharmacokinetic clearance of the anti-EGFR / HER3 ADC was determined in a colorectal cancer PDX model mouse. Specifically, a fragment of colorectal tumor (2 mm × 2 mm × 2 mm) derived from a patient was implanted into the right back of B-NDG mice. Mice were randomly assigned to groups (8 mice per group) according to tumor volume and were administered 9F3-3E1-CPT2 (G1, 6 mg / kg) or Ref4-CPT2 (G2, 8 mg / kg) via intravenous injection. Blood and tumor samples were collected at different time points.

[0403] Serum and tumor levels of the antibody and ADC were determined using a sandwich ELISA, and serum and tumor levels of CPT-2 release were determined using LC-MS / MS. The results are shown in the table below. The results showed that the half-lives of ADC, antibody, and CPT2 in tumor samples of group G1 were longer than those in group G2, and the Cmax of CPT2 in tumor samples of group G1 reached 8.120 ng / g, while that in group G2 was 6.370 ng / g. This indicates that 9F3-3E1-CPT2 can accumulate in tumors, exert its effects, and has a good half-life.

[0404] Table 18

[0405] Table 19

[0406] Humanized mouse models (e.g., dual-humanized EGFR / HER3 mice (B-hEGFR / hHER3 mice)) provide new tools for testing new treatment methods in clinical settings by significantly reducing the difference in clinical outcomes between humans and normal mice (expressing mouse EGFR or HER3). In another experiment, the pharmacokinetic clearance of anti-EGFR / HER3 ADC was determined in B-hEGFR / hHER3 mice. Specifically, B-hEGFR / hHER3 mice were divided into different groups (n=8 per group) and administered 9F3-3E1-CPT2 or Ref4-CPT2 intravenously. Control group mice were injected with ISO-CPT2. Blood samples were collected after injection.

[0407] Serum levels of antibodies and ADCs were measured using a sandwich ELISA. Similar to the results above, the 9F3-3E1-CPT2 results were consistent with typical pharmacokinetic characteristics.

[0408] Other Embodiments

[0409] It should be understood that although the invention has been described in conjunction with specific embodiments thereof, the foregoing description is intended to be illustrative and not to limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the appended claims. DescriptionPage 54 / 54 62 CN 122459348 A Figure 1 Appendix 1 of the Instruction Manual Page 63 CN 122459348 A Figure 2 Appendix 2 of the Instruction Manual Page 64 CN 122459348 A Figure 3 Appendix 3 of the Instruction Manual Page 65 CN 122459348 A Figure 3 (continued) Appendix 4 of the Instruction Manual Page 66 CN 122459348 A Figure 3 (continued) Appendix 5 of the Instruction Manual Page 67 CN 122459348 A Figure 4 Appendix 6 of the Instruction Manual Page 68 CN 122459348 A Figure 5 Appendix 7 of the Instruction Manual Page 69 CN 122459348 A Figure 6 Appendix 8 of the Instruction Manual Page 70 CN 122459348 A Figure 7 Appendix 9 of the Instruction Manual Page 71 CN 122459348 A Figure 8 Instruction manual illustrations, page 10 / 19, figure 72, CN 122459348 A, figure 9; illustrations, page 11 / 19, figure 73, CN 122459348 A, figure 10; illustrations, page 12 / 19, figure 74, CN 122459348 A, figure 11; illustrations, page 13 / 19, figure 75, CN 122459348 A, figure 12; illustrations, page 14 / 19, figure 76, CN 122459348 A, figure 13; illustrations, page 15 / 19, figure 77, CN 122459348 A, figure 14; illustrations, page 16 / 19, figure 78, CN 122459348 A, figure 15; illustrations, page 17 / 19, figure 79, CN 122459348 A, figure 16; illustrations, page 18 / 19, figure 80, CN 122459348 A, figure 17; illustrations, page 19 / 19, figure 81, CN. 122459348 A

Claims

1. An anti-EGFR / HER3 antibody or its antigen-binding fragment, comprising: It contains a first antigen-binding domain that specifically binds to EGFR and a second antigen-binding domain that specifically binds to HER3.

2. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to claim 1, wherein the first antigen-binding domain comprises a first heavy chain variable region (VH1) and a first light chain variable region (VL1); and the second antigen-binding domain comprises a second heavy chain variable region (VH2) and a second light chain variable region (VL2).

3. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to claim 2, wherein... The first heavy chain variable region (VH1) includes complementarity-determining regions (CDRs) 1, 2, and 3, wherein the VH1 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR1 amino acid sequence, the VH1 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR2 amino acid sequence, and the VH1 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VH1 CDR3 amino acid sequence; and The first light chain variable region (VL1) comprises CDR1, 2, and 3, wherein the VL1 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VL1CDR1 amino acid sequence, the VL1 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VL1CDR2 amino acid sequence, and the VL1 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VL1CDR3 amino acid sequence. The selected VH1 CDR1, 2, and 3 amino acid sequences and the selected VL1 CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 4-6, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (2) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (4) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 22-24, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (5) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 25-27, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; and (6) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 28-30, and the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3.

4. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to claim 2 or 3, wherein... The second heavy chain variable region (VH2) comprises CDR1, 2, and 3, wherein the VH2 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VH2CDR1 amino acid sequence, the VH2 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VH2CDR2 amino acid sequence, and the VH2 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VH2CDR3 amino acid sequence; and The second light chain variable region (VL2) comprises CDR1, 2, and 3, wherein the VL2 CDR1 region contains an amino acid sequence having at least 80% identity with a selected VL2CDR1 amino acid sequence, the VL2 CDR2 region contains an amino acid sequence having at least 80% identity with a selected VL2CDR2 amino acid sequence, and the VL2 CDR3 region contains an amino acid sequence having at least 80% identity with a selected VL2CDR3 amino acid sequence. The selected VH2 CDR1, 2, and 3 amino acid sequences and the selected VL2 CDR1, 2, and 3 amino acid sequences are one of the following: (1) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (2) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (3) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (4) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 31-33, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; (5) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 34-36, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, respectively; and (6) The selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 37-39, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3.

5. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-4, wherein... (1) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 4-6, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3. (2) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 7-9, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3. (3) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 13-15, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3. (4) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 16-18, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3; or (5) The selected VH1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 10-12, the selected VL1 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3, the selected VH2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 19-21, and the selected VL2 CDR1, 2, and 3 amino acid sequences are shown in SEQ ID NO: 1-3.

6. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 41, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO:

40.

7. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 42, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO:

40.

8. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 44, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO:

40.

9. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 45, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO:

40.

10. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-5, wherein the first heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 43, the first light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 40, the second heavy chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO: 46, and the second light chain variable region comprises a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity with SEQ ID NO:

40.

11. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-10, wherein the VH1 comprises an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL1 comprises an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) The selected VH sequence is SEQ ID NO: 41, and the selected VL sequence is SEQ ID NO: 40; (2) The selected VH sequence is SEQ ID NO: 42, and the selected VL sequence is SEQ ID NO: 40; and (3) The selected VH sequence is SEQ ID NO: 43, and the selected VL sequence is SEQ ID NO:

40.

12. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-11, wherein the VH1 comprises VH1 CDR1, VH1 CDR2, and VH1 CDR3 identical to the selected VH sequences; and the VL1 comprises VL1 CDR1, VL1 CDR2, and VL1 CDR3 identical to the selected VL sequences, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) The selected VH sequence is SEQ ID NO: 41, and the selected VL sequence is SEQ ID NO: 40; (2) The selected VH sequence is SEQ ID NO: 42, and the selected VL sequence is SEQ ID NO: 40; and (3) The selected VH sequence is SEQ ID NO: 43, and the selected VL sequence is SEQ ID NO:

40.

13. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-12, wherein the VH2 comprises an amino acid sequence having at least 90% identity with a selected VH sequence, and the VL2 comprises an amino acid sequence having at least 90% identity with a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) The selected VH sequence is SEQ ID NO: 44, and the selected VL sequence is SEQ ID NO: 40; (2) The selected VH sequence is SEQ ID NO: 45, and the selected VL sequence is SEQ ID NO: 40; and (3) The selected VH sequence is SEQ ID NO: 46, and the selected VL sequence is SEQ ID NO:

40.

14. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-13, wherein the VH2 comprises VH2 CDR1, VH2 CDR2, and VH2 CDR3 identical to the selected VH sequences; and the VL2 comprises VL2 CDR1, VL2 CDR2, and VL2 CDR3 identical to the selected VL sequences, wherein the selected VH sequence and the selected VL sequence are one of the following: (1) The selected VH sequence is SEQ ID NO: 44, and the selected VL sequence is SEQ ID NO: 40; (2) The selected VH sequence is SEQ ID NO: 45, and the selected VL sequence is SEQ ID NO: 40; and (3) The selected VH sequence is SEQ ID NO: 46, and the selected VL sequence is SEQ ID NO:

40.

15. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-14, wherein the VH1 comprises the sequence of SEQ ID NO: 41 and the VL1 comprises the sequence of SEQ ID NO:

40.

16. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-14, wherein the VH1 comprises the sequence of SEQ ID NO: 42 and the VL1 comprises the sequence of SEQ ID NO:

40.

17. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-14, wherein the VH1 comprises the sequence of SEQ ID NO: 43 and the VL1 comprises the sequence of SEQ ID NO:

40.

18. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-17, wherein the VH2 comprises the sequence of SEQ ID NO: 44 and the VL2 comprises the sequence of SEQ ID NO:

40.

19. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-17, wherein the VH2 comprises the sequence of SEQ ID NO: 45 and the VL2 comprises the sequence of SEQ ID NO:

40.

20. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-17, wherein the VH2 comprises the sequence of SEQ ID NO: 46 and the VL2 comprises the sequence of SEQ ID NO:

40.

21. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 1-20, wherein the first antigen-binding domain specifically binds to human or monkey EGFR; and / or the second antigen-binding domain specifically binds to human or monkey HER3.

22. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 1-21, wherein the first antigen-binding domain is human or humanized; and / or the second antigen-binding domain is human or humanized.

23. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 1-22, wherein the antibody is a multispecific antibody (e.g., a bispecific antibody).

24. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 1-23, wherein the first antigen-binding domain is a single-chain variable fragment (scFv); and / or the second antigen-binding domain is scFv.

25. The anti-EGFR / HER3 antibody or its antigen-binding fragment according to any one of claims 2-24, wherein the first light chain variable region and the second light chain variable region are identical.

26. An anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof cross-competes with the anti-EGFR / HER3 antibody or antigen-binding fragment thereof according to any one of claims 1-25.

27. A nucleic acid comprising a polynucleotide encoding an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as described in any one of claims 1-26.

28. A vector comprising the nucleic acid of claim 27.

29. A cell comprising the carrier of claim 28.

30. The cell of claim 29, wherein the cell is a CHO cell.

31. A cell comprising the nucleic acid of claim 27.

32. A method for generating an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof, the method comprising: (a) The cells are cultured under conditions sufficient to cause the cells of any one of claims 29-31 to produce the anti-EGFR / HER3 antibody or its antigen-binding fragment; and (b) Collect the anti-EGFR / HER3 antibody or its antigen-binding fragment produced by the cells.

33. An anti-EGFR / HER3 antibody-drug conjugate (ADC), said antibody-drug conjugate comprising the anti-EGFR / HER3 antibody or its antigen-binding fragment as described in any one of claims 1-26, covalently bound to a therapeutic agent.

34. The anti-EGFR / HER3 antibody drug conjugate according to claim 33, wherein the therapeutic agent is a cytotoxic agent or a cell growth inhibitor.

35. The anti-EGFR / HER3 antibody drug conjugate according to claim 33 or 34, wherein the therapeutic agent is MMAE or MMAF.

36. The antibody-drug conjugate of claim 33, wherein the therapeutic agent is selected from... (CPT-1), (CPT-2), (CPT-3) or (CPT-4).

37. The antibody-drug conjugate according to claim 33 or 36, wherein the therapeutic agent is linked to the antibody or its antigen-binding fragment via a linker.

38. The antibody-drug conjugate according to claim 37, wherein the linker has the following structure: 。 39. The antibody-drug conjugate according to any one of claims 33 and 36-38, wherein the antibody-drug conjugate has the following structure: or , Where n = 1-8; and "Ab" represents the antibody or its antigen-binding fragment.

40. A method for treating a subject suffering from cancer, the method comprising: The subject is given a therapeutically effective amount of the composition, the composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof according to any one of claims 1-26, or an anti-EGFR / HER3 antibody drug conjugate according to any one of claims 33-39.

41. The method of claim 40, wherein the subject has cancer expressing EGFR and / or HER3 (e.g., expressing both EGFR and HER3).

42. The method according to claim 40 or 41, wherein the cancer is esophageal cancer, colorectal cancer, gastric cancer, breast cancer, endometrial cancer, lung cancer, melanoma, ovarian cancer, bladder cancer, non-Hodgkin's lymphoma, head and neck cancer, pancreatic cancer, and cervical cancer.

43. The method according to any one of claims 40-42, wherein the subject is a human.

44. The method according to any one of claims 40-43, wherein the method further comprises administering an anti-PD1 antibody to the subject.

45. The method according to any one of claims 40-44, wherein the method further comprises administering chemotherapy to the subject.

46. ​​A method for reducing tumor growth rate, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as claimed in any one of claims 1-26, or an anti-EGFR / HER3 antibody drug conjugate as claimed in any one of claims 33-39.

47. A method for killing tumor cells, the method comprising contacting the tumor cells with an effective amount of a composition comprising an anti-EGFR / HER3 antibody or an antigen-binding fragment thereof as claimed in any one of claims 1-26, or an anti-EGFR / HER3 antibody drug conjugate as claimed in any one of claims 33-39.

48. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and (a) The anti-EGFR / HER3 antibody or its antigen-binding fragment as described in any one of claims 1-26, and / or (b) The anti-EGFR / HER3 antibody drug conjugate according to any one of claims 33-39.

49. An anti-EGFR / HER3 antibody-drug conjugate (ADC), the antibody-drug conjugate comprising a therapeutic agent covalently bound to a bispecific antibody or an antigen-binding fragment thereof, the bispecific antibody or antigen-binding fragment comprising a first antigen-binding domain specifically binding to EGFR and a second antigen-binding domain specifically binding to HER3.